Abstract
It is axiomatic that the appropriate treatment of arrhythmias requires that each arrhythmia be correctly diagnosed. An awareness of the factors contributing to the arrhythmia, the setting of appropriate therapeutic goals, familiarity with available drugs, and documentation of efficacy are also essential elements of antiarrhythmic therapy. In this chapter, we will discuss the clinical approach to the therapy of cardiac arrhythmias by considering the general points raised above. We will discuss the specific indications, clinical pharmacology, and toxicity of the various drugs currently employed in the United States and will consider the prophylactic use of antiarrhythmic drugs in order to prevent sudden cardiac death in populations at risk.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Pick A, Langendorf R: Differentiation of supraventricular and ventricular tachycardias. Prog Cardiovasc Dis 2: 391–407, 1960.
Kistin AD: Problems in the differentiation of ventricular arrhythmias from supraventricular arrhythmia with abnormal QRS. Prog Cardiovasc Dis 9:1, 1966.
Marriott HJL, Sandler JA: Criteria, old and new, for differentiating between ectopic ventricular beats and aberrant ventricular conduction in the presence of atrial fibrillation. Prog Cardiovasc Dis 9:18, 1966.
Massumi RA, Tawakkol AA, Kistin AD: Re-evaluation of electrocardiographic and bedside criteria for diagnosis of ventricular tachycardia. Circulation 36:628, 1967.
Wellens HJJ, Bar FWHM, Lie KI: The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med 64:27–33, 1978.
McHenry PL, Fisch C, Jordan JW, Corya BR: Cardiac arrhythmias observed during maximal treadmill exercise testing in clinically normal men. Am J Cardiol 29:331–336, 1972.
Blackburn H, Taylor HL, Hamrell B, Buskirk E, Nicholas WC, Thorsen RD: Premature ventricular complexes induced by stress testing: their frequency and response to physical conditioning. Am J Cardiol 31:441–449, 1973.
Frolicher VF, Thomas MM, Pillow C, Lancaster MC: Epidemiologic study of asymptomatic men screened by maximal treadmill testing for latent coronary artery disease. Am J Cardiol 34:770–776, 1974.
Jelinek MV, Lown B: Exercise stress testing for exposure of cardiac arrhythmias. Prog Cardiovasc Dis 16:497–522, 1974.
DeMaria AN, Vera Z, Amsterdam EA, Mason DT, Massumi R: Disturbances of cardiac rhythm and conduction induced by exercise: diagnostic, prognostic and therapeutic implications. Am J Cardiol 33:732–736, 1974.
McHenry PL, Morris SN, Kavalier M, Jordan JW: Comparative study of exercise-induced ventricular arrhythmias in normal subjects and patients with documented coronary artery disease. Am J Cardiol 37:609–616, 1976.
Goldschlager N, Cohn K, Goldschlager A: Exercise-related ventricular arrhythmias. Cardiovasc Dis 48:67–71, 1979.
Sheps DS, Ernst JC, Briese FR, Lopez LV, Conde CA, Castellanos A, Myerburg RJ: Decreased frequency of exercise-induced ventricular ectopic activity in the second of two consecutive treadmill tests. Circulation 55:892–895, 1977.
Faris JV, McHenry PL, Jordan JW, Morris SN: Prevalence and reproducibility of exercise-induced ventricular arrhythmias during maximal exercise testing in normal men. Am J Cardiol 37:617–622, 1976.
Ekblom B, Hartley LH, Day WC: Occurrence and reproducibility of exercise-induced ventricular ectopy in normal subjects. Am J Cardiol 43:35–40, 1979.
Lown B, Graboys TB: Management of patients with malignant ventricular arrhythmias. Am J Cardiol 39:910–918, 1977.
Gey GO, Levy RH, Fisher L, Pettet G, Bruce RA: Plasma concentration of procainamide and prevalence of exertional arrhythmias. Ann Intern Med 80:718–722, 1974.
Gettes LS, Surawicz B: Long-term prevention of paroxysmal arrhythmias with propranolol therapy. Am J Med Sci 254:257–265, 1967.
Gey GO, Levy RH, Pettet G, Fisher L: Quinidine plasma concentration and exertional arrhythmia. Am Heart J 90:19–24, 1975.
Talbot S, Kilpatrick D, Krikler D, Oakley CM: Ventricular tachycardia due to cardiac ischaemia: assessment by exercise electrocardiography. Br Med J 2:733–736, 1978.
LeWinter MM, Engler RL, Karliner JS: Tocainide therapy for treatment of ventricular arrhythmias: assessment with ambulatory electrocardiographic monitoring and treadmill exercise. Am J Cardiol 45:1045–1052, 1980.
Markiewicz W, Houston N, DeBusk RG: Exercise testing soon after myocardial infarction. Circulation 56:26–31, 1977.
Sami M, Kraemer H, DeBusk RF: Reproducibility of exercise-induced ventricular arrhythmia after myocardial infarction. Am J Cardiol 43:724–730, 1979.
DeBusk RF, Haskell W: Symptom-limited vs heart-rate-limited exercise testing soon after myocardial infarction. Circulation 61:738–743, 1980.
Hinkle LE, Carver ST, Stevens M: The frequency of asymptomatic disturbances of cardiac rhythm and conduction in middle-aged men. Am J Cardiol 24:629–650, 1969.
Bleifer SB, Bleifer DJ, Hansmann DR, Sheppard JJ, Darpman HL: Diagnosis of occult arrhythmias by Holter electrocardiography. Prog Cardiovasc Dis 16:569–599, 1974.
Harrison DC, Fitzgerald JW, Winkle RA: Ambulatory electrocardiography for diagnosis and treatment of cardiac arrhythmias. N Engl J Med 294:373–380, 1976.
Winkle RA: Ambulatory electrocardiography. Mod Concepts Cardiovasc Dis 49:7–12, 1980.
Ryan M, Lown B, Horn H: Comparison of ventricular ectopic activity during 24-hour monitoring and exercise testing in patients with coronary heart disease. N Engl J Med 292:224–229, 1975.
Morganroth J, Michelson EL, Horowitz LN, Josephson ME, Pearlman AS, Dunkman WB: Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency. Circulation 58:408–414, 1978.
Michelson EL, Morganroth J: Spontaneous variability of complex ventricular arrhythmias detected by long-term electrocardiographic recording. Circulation 61:690–695, 1980.
Sami M, Kraemer H, Harrison DC, Houston N, Shimasaki C, DeBusk RF: A new method for evaluating antiarrhythmic drug efficacy. Circulation 62:1172–1179, 1980.
Bigger JT Jr, Goldreyer BN: The mechanism of supraventricular tachycardia. Circulation 42:673–688, 1970.
Josephson ME, Kastor JA: Supraventricular tachycardia: mechanisms and management. Ann Intern Med 87: 346–358, 1977.
Denes P, Wu D, Amat-y-Leon F, Dhingra R, Wyndham C, Kehoe R, Ayres BF, Rosen KM: Paroxysmal supraventricular tachycardia induction in patients with Wolff-Parkinson-White syndrome. Ann Intern Med 90:153–157, 1979.
Wellens HJ, Schuilenburg RM, Durrer D: Electrical stimulation of the heart in patients with ventricular tachycardia. Circulation 46:216–226, 1972.
Denes P, Wu D, Dhingra RC, Amat-y-Leon F, Wyndham C, Mautner RK, Rosen KM: Electrophysiological studies in patients with chronic recurrent ventricular tachycardia. Circulation 54:229–236, 1976.
Josephson ME, Horowitz LN: Electrophysiologic approach to therapy of recurrent sustained ventricular tachycardia. Am J Cardiol 43:631–642, 1979.
Vandepol CJ, Farshidi A, Spielman SR, Greenspan AM, Horowitz LN, Josephson ME: Incidence and clinical significance of induced ventricular tachycardia. Am J Cardiol 45:725–731, 1980.
Wellens HJJ, Duren DR, Lie KI: Observations on mechanisms of ventricular tachycardia in man. Circulation 54:237–244, 1976.
Mason JW, Winkle RA: Electrode-catheter arrhythmia induction in the selection and assessment of antiarrhythmic drug therapy in recurrent ventricular tachycardia. Circulation 58:971–985, 1978.
Reddy CP, Gettes LS: Use of isoproterenol as an aid to electric induction of chronic recurrent ventricular tachycardia. Am J Cardiol 44:705–713, 1979.
Horowitz LN, Josephson ME, Farshidi A, Spielman SR, Michelson EL, Greenspan AM: Recurrent sustained ventricular tachycardia. 3. Role of the electrophysiologic study in selection of antiarrhythmic regimens. Circulation 58: 986–997, 1978.
Wellens HJJ: Value and limitations of programmed electrical stimulation of the heart in the study and treatment of tachycardias. Circulation 57:845–853, 1978.
Mason JW, Winkle R A: Accuracy of the ventricular tachycardia induction study for predicting long-term efficacy and inefficacy of antiarrhythmic drugs. N Engl J Med 103: 1073–1077, 1980.
Bigger JT Jr, Hoffman BF: Antiarrhythmic drugs. In: Gilman AG, Goodman LS, Gilman A (eds) The Pharmacological Basis of Therapeutics. Macmillan, New York, 1980, pp 761–792.
Gettes LS, McAllister R, Chen C-M: Electropharmacology and clinical pharmacology of antiarrhythmic drugs. In: Eliot RS, Wolf GL, Forker AD (eds), Cardiac Emergencies. Futura Publ, New York, 1977, pp 245–282.
Singh BN, Collett JT, Chew CYC: New perspectives in the pharmacologic therapy of cardiac arrhythmias. Prog Cardiovasc Dis 22:243–301, 1980.
Sada H, Tan T, Oshita S: Effects of mexiletine on transmembrane action potentials as affected by external potassium concentration and by rate of stimulation in guinea-pig papillary muscles. Clin Exp Pharmacol Physiol 7: 583–593, 1980.
Oshita S, Sada H, Kojima M, Ban T: Effects of tocainide and lidocaine on the transmembrane action potentials as related to external potassium and calcium concentrations in guinea-pig papillary muscles. Arch Pharmacol 314: 67–82, 1980.
Greenblatt DJ, Balognini V, Koch-Weser J, Harmatz JS: Pharmacokinetic approach to the clinical use of lidocaine intravenously. J Am Med Assoc 236: 273–277, 1976.
Collingsworth KA, Kalman SM, Harrison DC: The clinical pharmacology of lidocaine as an antiarrhythmic drug. Circulation 50:1217–1230, 1974.
Harrison DC, Meffin PJ, Winkle RA: Clinical pharmacokinetics of antiarrhythmic drugs. Prog Cardiovasc Dis 20:217–242, 1977.
Woosley RL, Shand DG: Pharmacokinetics of antiarrhythmic drugs. Am J Cardiol 41:986–995, 1978.
Bernowitz NL, Meister W: Clinical pharmacokinetics of lidocaine. Clin Pharmacokinet 3:177–201, 1978.
Rodman JH: Lidocaine. In: Evans WE, Schentag JJ, Jusko WJ (eds), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Applied Therapeutics, San Francisco, 1980, pp 350–391.
Lie KF, Wellens HJ, Van Capelle FJ, Durrer D: Lidocaine in the prevention of primary ventricular fibrillation: a double-blind randomized study of 212 consecutive patients. N Engl J Med 291:1324–1326, 1974.
Noneman JW. Rogers JF: Lidocaine prophylaxis in acute myocardial infarction. Medicine 57:501–515, 1978.
DeSilva RA, Hennekins CH, Lown B, Casscells W: Lignocaine prophylaxis in acute myocardial infarction: an evaluation of randomized trials. Lancet 2:855–858, 1981.
Bleifeld W, Merx W, Heinrich KW, Effert S: Controlled trial of prophylactic treatment with lidocaine in acute myocardial infarction. Eur J Clin Pharmacol 6:119–126, 1973.
Bennett MA, Wilner JM, Pentecost BL: Controlled trial of lignocaine in prophylaxis of ventricular arrhythmias complicating myocardial infarction. Lancet 2:909–911, 1970.
Mogensen I: Ventricular tachyarrhythmias and lignocaine prophylaxis in acute myocardial infarction. Acta Med Scand [Suppl] 513:1–80, 1970.
O’Brien KP, Taylor PM, Corxson RS: Prophylactic lignocaine in hospitalized patients with acute myocardial infarction. Med J Aust 2 (Suppl):36–37, 1973.
Church G, Biern R: Prophylactic lidocaine in acute myocardial infarction. Circulation 45–46 (Suppl II):II-139, 1972 (abstract).
Ribner HS, Isaacs ES, Frishman WH: Lidocaine prophylaxis against ventricular fibrillation in acute myocardial infarction. Prog Cardiovasc Dis 21:287–313, 1979.
Harrison DC: Should lidocaine be administered routinely to all patients after acute myocardial infarction? Circulation 58:581–584, 1978.
Valentine PA, Frew JL, Mashford ML, Sloman JG: Lidocaine in the prevention of sudden death in the pre-hospital phase of acute infarction. N Engl J Med 291:1327–1331, 1974.
Sandler G, Dey N, Amonkar J: Prophylactic intramuscular lidocaine in myocardial infarction. Curr Ther Res 20:563–571, 1976.
Lie KI, Liem KL, Louridtz WJ, Janse MH, Willebrands AF, Durrer D: Efficacy of lidocaine in preventing primary ventricular fibrillation within 1 hour after a 300 mg intramuscular injection: a double-blind, randomized study of 300 hospitalized patients with acute myocardial infarction. Am J Cardiol 42:486–488, 1978.
Danahy DT, Aronow WS: Lidocaine-induced cardiac rate changes in atrial fibrillation and atrial flutter. Am Heart J 95:474–482, 1978.
Akhtar M, Gilbert CJ, Shenasa M: Effect of lidocaine on atrioventricular response via the accessory pathway in patients with Wolff-Parkinson-White syndrome. Circulation 63:435–551, 1981.
Huet PM, Lelorier J, Pomier G, Marleau D: Bioavailability of lidocaine in normal volunteers and cirrhotic patients. Gastroenterology 75:969, 1978 (abstract).
Boyes RN, Scott DB, Jebson PJ, Godman MJ, Julian DG: Pharmacokinetics of lidocaine in man. Clin Pharmacol Ther 12:105–116, 1971.
Stenson RE, Constantine RT, Harrison DC: Interrelationships of hepatic blood flow, cardiac output and blood levels of lidocaine in man. Circulation 43:205–211, 1971.
Rowland M, Thomson PD, Uiuchard A, Melmon RL: Disposition kinetics of lidocaine in normal subjects. Ann NY Acad Sci 179: 383–398, 1971.
Ochs HR, Carstens G, Greenblatt DJ: Reduction in lidocaine clearance during continuous infusion and by coad- ministration of propranolol. N Engl J Med 303:373–377, 1980.
Thomson PD, Melmon KE, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M: Lidocaine pharmacokinetics in advanced heart failure, liver disease and renal failure in humans. Ann Intern Med 78:499–508, 1973.
Bax NDS, Tucker GT, Woods HF: Lignocaine and indo-cyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmacol 10: 353–361, 1980.
Nation R, Triggs EJ, Selig M: Lignocaine kinetics in cardiac patients and aged subjects. Br J Clin Pharmacol 4:439–448, 1977.
Cusack B, Kelly JG, Lavan J, Neol J, O’Malley K: Pharmacokinetics of lignocaine in the elderly. Br J Clin Pharmocol 9:293P-294P, 1980 (abstract).
LeLorier J, Grenon D, Latour Y, Caille G, Dumont G, Brosseau A, Solignac A: Pharmacokinetics of lidocaine after prolonged intravenous infusions in uncomplicated myocardial infarctions. Ann Intern Med 87:700–702, 1977.
Prescott LF, Adjepon-Yamoah KK, Talbet RG: Impaired lidocaine metabolism in patients with myocardial infarction and cardiac failure. Br Med J 1:939–941, 1976.
Sawyer DR, Ludden TM, Crawford MH: Continuous infusion of lidocaine in patients with cardiac arrhythmias: unpredictability of plasma concentrations. Arch Intern Med 141:43–45, 1981.
Aps C, Bell JA, Jenkins BS, Poole-Wilson PA, Reynolds F: Logical approach to lignocaine therapy. Br Med J 1:13–15, 1975.
Zito RA, Reid PR: Lidocaine kinetics predicted by indocyanine green clearance. N Engl J Med 298:1160–1163, 1978.
Routledge PA, Stargel WW, Wagner GS, Shand DG: Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Intern Med 93:701–704, 1980.
Pieper JA, Wyman MG, Goldreyer BN, Cannon DS, Slaughter RL, Lalka D: Lidocaine toxicity: effects of total vs free lidocaine concentrations. Circulation 62 (Suppl III):III-181, 1980 (abstract).
Piafsky KM, Knoppert D: Binding of local anesthetics to alpha-1-acid glycoprotein. Clin Res 26:836A, 1978 (abstract).
Zener JC, Kerber RE, Spivack AP, Harrison DC: Blood lidocaine levels and kinetics following high dose intramuscular administration. Circulation 47:984–988, 1973.
Cohen LS, Rosenthal JE, Horner DW Jr, Atkins JM, Matthews OA, Sarnoff SJ: Plasma levels of lidocaine after intramuscular administration. Am J Cardiol 29:520–523, 1972.
Ryden L, Wasir H, Conradsson TB, Olsson B: Blood levels of lignocaine after intramuscular administration to patients with proven or suspected acute myocardial infarction. Br Heart J 34:1012–1017, 1972.
Wyman MG, Lalka D, Hammersmith L, Cannon DS, Goldreyer BN: Multiple bolus technique for lidocaine administration during the first hours of an acute myocardial infarction. Am J Cardiol 41:313–317, 1978.
Stargel WW, Shand DG, Routledge PA, Barchowsky A, Wagner GS: Clinical comparison of rapid infusion and multiple injection methods for lidocaine loading. Am Heart J 102:872–876, 1981.
DiFazio LA, Brown RB: Lidocaine metabolism in normal and phenobarbitol pre-treated dogs. Anesthesiology 36: 238–243, 1972.
Heinonen J: Influence of some drugs on toxicity and rate of metabolism of lidocaine and mepivacaine. Ann Med Exp Biol Fenn 44 (Suppl III): 1–43, 1966.
Heinonen J, Takki S, Jarho L: Plasma lidocaine levels in patients treated with potential inducers of microsomal enzymes. Acta Anaesthesiol Scand 14:89–95, 1970.
Pape BE, Whiting R, Parker KM, Mitra R: Enzyme immunoassay and gas-liquid chromatography compared for determination of lidocaine in serum. Clin Chem 24: 2020–2022, 1978.
Buckman K, Claiborne K, de Guzman M, Walberg CB, Haywood LJ: Lidocaine efficacy and toxicity assessed by a new, rapid method. Clin Pharmacol Ther 28:177–181, 1980.
Pfeifer HJ, Greenblatt, DJ Koch-Weser J: Clinical use and toxicity of intravenous lidocaine. Am Heart J 92:168–173, 1976.
Lippestad CT, Forfang K: Production of sinus arrest by lignocaine. Br Med J 1:537, 1971.
Cheng TO, Wadwha K: Sinus standstill following intravenous lidocaine administration. J Am Med Assoc 223: 790–792, 1973.
Levy S, Balansard P, Bouteau JM, Gerard R: L’arrêt sinusal: complication grave de la lidocaine intraveineuse Arch Mal Coeur 68:1069–1073, 1975.
Klein HO, Jutrin I, Kaplinsky E: Cerebral and cardiac toxicity of a small dose of lignocaine. Br Heart J 37: 775–778, 1975.
Manyari-Ortega DE, Brennan FJ: Lidocaine-induced cardiac asystole. Chest 74:227–229, 1978.
Lichstein E, Chadda KD, Gupta PK: Atrioventricular block with lidocaine therapy. Am J Cardiol 31:277–281, 1973.
Josephson ME, Caracta AR, Lau SH, Gallagher JJ, Damato AN: Effects of lidocaine on refractory periods in man. Am Heart J 84:778–786, 1972.
Gianelly RE, von der Groeben JO, Spivack AP, Harrison DC: Effects of lidocaine on ventricular arrhythmias in patients with coronary heart disease. N Engl J Med 277:1215–1219, 1967.
Gupta PK, Lichstein E, Chadda KD: Lidocaine-induced heart block in patients with bundle branch block. Am J Cardiol 33:487–492, 1974.
Kunkel F, Rowland M, Scheinman MM: The electrophysiologic effects of lidocaine in patients with intraventricular conduction defects. Circulation 49:894–899, 1974.
Aravandakshan V, Kuo CS, Gettes LS: Effect of lidocaine on escape rate in patients with complete atrial ventricular block. Am J Cardiol 40:177–183, 1977.
Kuo CS, Reddy CP: Effect of lidocaine on escape rates in patients with complete atrioventricular block: B. Proximal His bundle block. Am J Cardiol 47:1315–1320, 1981.
Leahy EB Jr, Bigger JT: Mexiletine: a new antiarrhythmic drug. Ann Intern Med 92:427–429, 1980.
Chew CYC, Collett J, Singh BN: Mexiletine: A review of its pharmacological properties and therapeutic efficacy in arrhythmias. Drugs 17:161–181, 1979.
Kulbertus HE: Clinical antiarrhythmic efficacy of mexiletine: a review. Acta Cardiol Suppl 25: 111–120, 1980.
Danilo P Jr: Mexiletine. Am Heaft J 97:399–403, 1979.
Jewitt D, McComish M, Jackson G: Ambulatory monitoring in the controlled assessment of antiarrhythmic drug therapy. Postgrad Med J 5 (Suppl 7):67–71, 1976.
VanDurme JP, Bogaert M, Weyne T, Pannier R: Comparison of the antidysrhythmic efficacy of mexiletine, isocainide and placebo. Circulation 55–56(Suppl III):III-176, 1977 (abstract).
Talbot RG, Julian DG, Prescott LF: Long term treatment of ventricular arrhythmias with oral mexiletine. Am Heart J 91: 58–65, 1976.
Abinader EG, Cooper M: Mexiletine: use in control of chronic drug resistant ventricular arrhythmias. J Am Med Assoc 242:337–339, 1979.
Campbell NPS, Pantridge JF, Adgey AAJ: Mexiletine in the management of ventricular dysrhythmias. Eur J Cardiol 6:245–258, 1977.
Campbell RWF, Achuff SC, Pottage A, Murray A, Prescott LF, Julian DG: Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction. J Cardiovasc Pharmacol 1:43–52, 1979.
Talbot RG, Clark RA, Nimmo J, Nielsson JMM, Julian DG, Prescott LF: Treatment of ventricular arrhythmias with mexiletine (Ko 1173). Lancet 2:399–404, 1973.
Heger JJ, Nattel S, Rinkenberger RL, Zipes DP: Mexiletine therapy in 15 patients with drug-resistant ventricular tachycardia. Am J Cardiol 45:627–632, 1980.
Friedman IM, Simpson RJ, Foster JR, Gettes LS: Mexiletine: an effective drug in preventing refractory recurrent ventricular tachycardias. Circulation 62 (Suppl III): III-154, 1980 (abstract).
Chamberlain DA, Julian DG, Boyle DM, Jewitt DE, Campbell RWF, Shanks RG: Oral mexiletine in high-risk patients after myocardial infarction. Lancet 2:1324–1327, 1980.
McComish M, Robinson C, Kitson D, Jewitt D: Clinical electrophysiologic effect of mexiletine. Postgrad Med J 53 (Suppl I): 85–91, 1977.
Duff HJ, Roden DM, Primm K, Carey EL, Oates JA, Woosley RL: Mexiletine for resistant ventricular tachycardia: comparison with lidocaine and enhancement of efficacy by combination with quinidine. Am J Cardiol 47: 438, 1981 (abstract).
Campbell NPS, Kelly JG, Adgey AAJ, Shanks RG: The clinical pharmacology of mexiletine. Br J Clin Pharmacol 6:103–108, 1978.
Campbell NPS, Kelly JG, Adgey AAJ, Shanks RG: Mexiletine in normal volunteers. Br J Clin Pharmacol 6: 372–373, 1978.
Prescott LF, Clements JA, Pottage A: Absorption, distribution and elimination of mexiletine. Postgrad Med J 53 (Suppl I):50–55, 1977.
Baudinet G, Henrard L, Quinaux N, el Allaf D, De Laudsheere C, Carlier J, Dresse A: Pharmacokinetics of mexiletine in renal insufficiency. Acta Cardiol Suppl XXV: 55–65, 1980.
Bogaert M: Adaptation of the dose of mexiletine according to pharmacokinetic data. Acta Cardiol Suppl XXV:67–73, 1980.
Ruskin JN, DiMarco JP, Garan H: Out-of-hospital cardiac arrest: Electrophysiologic observations and selection of long-term antiarrhythmic therapy. N Engl J Med 303: 607–613, 1980.
Leahey EB, Heissenbuttel RJ, Bigger JT: Combined mexiletine andpropranolol for resistant ventricular arrhythmias. Circulation 62 (Suppl III) III-181, 1980 (abstract).
Breithardt G, Seipel L, Abendroth RR: Comparative crossover study of the effects of disopyramide and mexiletine on stimulus-induced ventricular tachycardia. Circulation 62 (Suppl III):III-153, 1980 (abstract).
Meinertz T, Kasper W, Kersting F, Bechtold H, Jahnchen E, Lollgen H, Just H: Comparison of the antiarrhythmic activity of mexiletine and lorcainide on refractory ventricular arrhythmias. Circulation 62 (Suppl III):III-184, 1980 (abstract).
Stavenow L, Hanson A, Johansson BW: Mexiletine in treatment of ventricular arrhythmias: a long-term follow-up. Acta Med Scand 205:411–415, 1979.
Paalman ACA, Roos JC, Siebelink J, Dunning AJ: Development of a dosage scheme for simultaneous intravenous and oral administration of mexiletine. Postgrad Med J 53 (Suppl I): 128–132, 1977.
Carlier J: Hemodynamic, electrocardiographic and toxic effects of the intravenous administration of increasing doses of mexiletine in the dog: comparison with similar effects produced by other antiarrhythmics. Acta Cardiol Suppl XXV:81–100, 1980.
Campbell NPS, Zaidi SA, Adgey AAJ, Patterson GC, Pantridge JF: Observations on haemodynamic effects of mexiletine. Br Heart J 41:182–186, 1979.
Renard M, De Hemptinne J, Gillet JM, Bernard R: Hemodynamic effects of parenteral and oral mexiletine. Acta Cardiol Suppl XXV:75–80, 1980.
Henrard L, Carlier J: Hemodynamic effects of an intravenous injection of mexiletine in patients hospitalized in intensive care units. Acta Cardiol Suppl XXV: 101–107, 1980.
Danilo P: Tocainide. Am Heart J 97:259–262, 1979.
Zipes DP, Troup PJ: New antiarrhythmic agents. Am J Cardiol 41:1005–1024, 1978.
Winkle RA, Meffin PJ, Fitzgerald JW, Harrison DC: Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic, tocainide. Circulation 54:884–889, 1976.
Woosley RL, McDevitt DG, Nies AS, Smith RF, Wilkinson GR, Oates JA: Suppression of ventricular ectopic depolarizations by tocainide. Circulation 56:980–984, 1977.
Ryan W, Engler R, LeWinter M, Karliner JS: Efficacy of a new oral agent (tocainide) in the acute treatment of refractory ventricular arrhythmias. Am J Cardiol 43:285–291, 1979.
Engler R, Ryan W, LeWinter M, Bluestein H, Kerliner JS: Assessment of long-term antiarrhythmic therapy: studies on the long-term efficacy and toxicity of tocainide. Am J Cardiol 43: 612–618, 1979.
Kuck KH, Hanrath P, Lubda J, Mathey D, Bleifeld W.: Die antiarrhythmische Wirkung von tocainid bei ventricu- laren Herzrhythmusstörungen. Dtsch Med Wochenschr 104:1701–1705, 1979.
Sonnhag C: Efficacy and tolerance of tocainide during acute and long-term treatment of chronic ventricular arrhythmias. Eur J Clin Pharmacol 18: 301–310, 1980.
McDevitt DG, Nies AS, Wilkinson GR, Smith RF, Woosley RL, Oates JA: Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2’,6’-propionoxylidide in man. Clin Pharmacol Ther 19:396–402, 1976.
Maloney JD, Nissen RG, McColgan JM: Open clinical studies at a referral center: chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents. Am Heart J 100:1023–1030, 1980.
Winkle RA, Mason JW, Harrison DC: Tocainide for drug-resistant ventricular arrhythmias: efficacy, side effects and lidocaine responsiveness for predicting tocainide success. Am Heart J 100:1031–1036, 1980.
Roden DM, Reele SB, Higgins SB, Carr RK, Smith RF, Oates JA, Woosley RL: Tocainide therapy for refractory ventricular arrhythmias. Am Heart J 100:15–22, 1980.
Koransky A, Kehoe R, Sherman M, Tommaso C, Myers S, Lesch M: Comparative effects of tocainide and lidocaine on sustained ventricular tachycardia. Circulation 64 (Suppl IV): IV-38, 1981 (abstract).
Waleffe A, Bruninx R, Mary-Rabine L, Kulbertus HE: Effects of tocainide studied with programmed electrical stimulation of the heart in patients with reentrant tachyarrhythmias. Am J Cardiol 43:292–299, 1979.
Graffner C, Conradson T, Hofvendahl S, Ryden L: Tocainide kinetics after intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction. Clin Pharmacol Ther 27: 64–71, 1980.
Lalka D, Meyer MB, Duce BR, Elvin AT: Kinetics of the oral lidocaine congener, tocainide. Clin Pharmacol Ther 19: 757–766, 1976.
Winkle RA, Meffin PJ, Harrison DC: Long-term tocainide therapy for ventricular arrhythmias. Circulation 57: 1008–1016, 1978.
Elvin AT, Keenaghan JB, Byrnes EW, Tenthorey PA, MCMaster PD, Takman BH, Lalka D, Manion CV, Baer DT, Wolshin EM, Meyer MB, Ronfeld RA: Conjugation of tocainide in man: a novel pathway of biotransformation for a primary amine. J Pharmocol Sci 69: 47–49, 1980.
Swedberg K, Pehrson J, Ryden L: Electrocardiographic and hemodynamic effects of tocainide (W-36095) in man. Eur J Clin Pharmacol 14:15–19, 1978.
Nyquist O, Forssel G, Norlander R, Schenck-Gustafsson K: Hemodynamic and antiarrhythmic effects of tocainide in patients with acute myocardial infarction. Am Heart J 100:1000–1005, 1980.
Winkle RA, Anderson JL, Peters F, Meffin PJ, Fowles RE, Harrison DC: The hemodynamic effects of intravenous tocainide in patients with heart disease. Circulation 57:787–792, 1978.
Haffajee CJ, Alpert JS, Dalen JE: Tocainide for refractory ventricular arrhythmias of myocardial infarction. Am Heart J 100: 1013–1016, 1980.
Horn H, Hadidian Z., Johnson JL, Vassallo HG, Williams JH, Young MD. Safety evaluation of tocainide in the American Emergency Use Program. Am Heart J 100: 1037–1040, 1980.
Ryan WF, Karliner JS: Effects of tocainide on left ventricular performance at rest and during acute alterations in heart rate and systemic arterial pressure: an echocardiographic study. Br Heart J 41:175–181, 1979.
Young MD, Hadidian Z, Horn HR, Johnson JL, Vassallo HG: Treatment of ventricular arrhythmias with oral tocainide. Am Heart J 100:1041–1045, 1980.
Atkinson AJ, Davison R: Diphenylhydantoin as an antiarrhythmic drug. Ann Rev Med 25:99–113, 1974.
Winkle RA, Glantz SA, Harrison DC: Pharmacologic therapy of ventricular arrhythmias. Am J Cardiol 36: 629–650, 1975.
Anderson JL, Harrison DC, Meffin PJ, Winkle RA: Antiarrhythmic drugs: clinical pharmacology and therapeutic uses. Drugs 15:271–309, 1978.
Bigger JT, Dresdale RJ, Heissenbussel RH, Weld FM, Wit AL: Ventricular arrhythmias in ischemic heart disease: mechanism, prevalence, significance and management. Prog Cardiovasc Dis 19:255–300, 1979.
Karliner JS: Intravenous diphenylhydantoin sodium (dilantin) in cardiac arrhythmias. Dis Chest 51:256–269, 1967.
Rosen M, Lisak R, Rubin IL: Diphenylhydantoin in cardiac arrhythmias. Am J Cardiol 20:674–678, 1967.
Conn RD: Diphenylhydantoin sodium in cardiac arrhythmias. N Engl J Med 272:277–282, 1965.
Mercer EN, Osborne JA: The current status of diphenylhydantoin in heart disease. Ann Intern Med 67:1084–1107, 1967.
Bigger JT Jr, Schmidt DH, Kutt H: Relationship between the plasma level of diphenylhydantoin sodium and its cardiac antiarrhythmic effects. Circulation 38: 363–374, 1968.
Mosey L, Tyler MD: The effect of diphenylhydantoin sodium (dilantin), procaine hydrochloride, procaine amide hydrochloride, and quinidine hydrochloride upon ouabain-induced ventricular tachycardia in unanesthetized dogs. Circulation 10:65–70, 1954.
Helfant RH, Scherlag BJ, Damato AN: Protection from digitalis toxicity with the prophylactic use of diphenylhydantoin sodium. Circulation 36:119–124, 1967.
Lang TW, Bernstein H, Barbieri F, Gold H, Corday E: Digitalis toxicity: treatment with diphenylhydantoin. Arch Intern Med 116:573–580, 1965.
Eddy JD, Singh SP: Treatment of cardiac arrhythmias with phenytoin. Br Med J 4:270–273, 1969.
Vajda FJE, Prineas RJ, Lovell RRH, Sloman JG: The possible effect of long-term high plasma levels of phenytoin on mortality after acute myocardial infarction. Eur J Clin Pharmacol 5:138–144, 1973.
Collaborative group: Phenytoin after recovery from myocardial infarction. Lancet 2:1055–1057, 1971.
Peter T, Ross D, Duffield A, Luxton M, Harper R, Hunt D, Sloman G: Effect on survival after myocardial infarction of long-term treatment with phenytoin. Br Heart J 40:1356–1360, 1978.
Stone N, Klein MD, Lown B: Diphenylhydantoin in the prevention of recurring ventricular tachycardia. Circulation 43:420–427, 1971.
Karlsson E: Procainamide and phenytoin: comparative studies of their antiarrhythmic effects at apparent therapeutic plasma levels. Br Heart J 37:731–740, 1975.
Krone RJ, Miller JP, Kleiger RE, Clark KW, Oliver GC: The effectiveness of antiarrhythmic agents on early-cycle premature ventricular complexes. Circulation 63:664–669, 1981.
Jung D, Powell JR, Walson P, Perrier D: Effect of dose on phenytoin absorption. Clin Pharmacol Ther 28:479–485, 1980.
Glazko AJ: Diphenylhydantoin. Pharmacology 8:163–177, 1972.
Albert KS, Sakmar E, Hallmark MR, Weidler DJ, Wagner JG: Bioavailability of diphenylhydantoin. Clin Pharmacol Ther 16:727–735, 1974.
Lund L, Alvan G, Berlin A, Alexanderson B: Pharmacokinetics of single and multiple doses of phenytoin in man. Eur J Clin Pharmacol 7:81–86, 1974.
Gugler R, Manion CV, Azarnoff DL: Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther 19: 135–142, 1976.
Jusko WJ, Koup JR, Alvan G: Nonlinear assessment of phenytoin bioavailability. J Pharmacokinet Biopharm 4:327–336, 1976.
Ludden TM, Allen JP, Schneider LW, Stavchansky SA: Rate of phenytoin accumulation in man: a simulation study. J Pharmacokinet Biopharm 6:399–415, 1978.
Kutt H, Winters W, Scherman R, McDowell F: Diphenylhydantoin and phenobarbital toxicity: the role of liver disease. Arch Neurol 11:649–656, 1964.
Blaschke TF, Meffin PJ, Melmon KL, Rowland M: Influence of acute viral hepatitis on phenytoin kinetics and protein binding. Clin Pharmacol Ther 17:685–691, 1975.
Olanow CW, Finn AL: Phenytoin: pharmacokinetics and clinical therapeutics. Neurosurgery 8:112–117, 1981.
Olanow CW, Finn AL, Prussak C: The effects of salicylate on the pharmacokinetics of phenytoin. Neurology 31: 341–342, 1981.
Richens A, Dunlop A: Serum phenytoin levels in management of epilepsy. Lancet 2:247–248, 1975.
Cranford RE, Leppik IE, Patrick B, Anderson CB, Kostick B: Intravenous phenytoin: clinical and pharmacokinetic aspects. Neurology 28:874–880, 1978.
Buchanan RA, Kinkel AW, Goulet JR, Smith TC: The metabolism of diphenylhydantoin (dilantin) following once-daily administration. Neurology 22:126–130, 1972.
Kostenbauder HB, Rapp RP, McGovern JP, Foster TS, Perrier DG, Blacker HM, Hulon WC, Kinkel AW: Bioavailability and single-dose pharmacokinetics: intramuscular phenytoin. Clin Pharmacol Ther 18:449–456, 1975.
Strandjord RE, Johanessen SI: One daily dose of diphenylhydantoin for patients with epilepsy. Epilepsia 15: 317–327, 1974.
Cocks DA, Critchley EMR, Hayward HW, Owen V, Mawer GE, Woodcock BG: Control of epilepsy with a single daily dose of phenytoin sodium. Br J Clin Pharmacol 2:449–453, 1975.
Mawer GE, Mullen PW, Rodgers M: Phenytoin dose adjustment in epileptic patients. Br J Clin Pharmacol 1:163–168, 1974.
Ludden TM. Allen JP. Valutskv WA. Vicuna AV. Nappi TM, Hoffman SF, Wallace JE, Lalka D, McNay JL: Individualization of phenytoin dosage regimens. Clin Pharmacol Ther 21:287–293, 1977.
Martin E, Tozer TN, Sheiner LB, Riegelman S: The clinical pharmacokinetics of phenytoin. J Pharmacokinet Biopharm 5: 579–596, 1977.
Mullen PW: Optimal phenytoin therapy: a new technique for individualizing dosage. Clin Pharmacol Ther 23:228–232, 1978.
Vozeh S, Koelz A, Martin E, Magun H, Scollo-Lavizzari G, Follath F: Predictability of phenytoin serum levels by nomograms and clinicians. Eur Neurol 0:345–352, 1980.
Data JL, Wilkinson GR, Nies AS: Interaction of quinidine with anticonvulsant drugs. N Engl J Med 294:699–702, 1976.
Fine A, Henderson IS, Morgan DR: Malabsorption of frusemide caused by phenytoin. Br Med J 2:1061–1062, 1977.
Bivins BA, Rapp RP, Griffen WO Jr, Blouin R, Bustrack J: Dopamine-phenytoin interaction: a cause of hypotension in the critically ill. Arch Surg 113:245–249, 1978.
Tibbs PA, Bivens BA, Rapp RP, Young AB, Griffon WO Jr, Haack DG: Phenytoin-induced hypotension in animals receiving sympathomimetic pressor support. J Surg Res 29:338–347, 1980.
Kutt H, Winters W, Kokenge R, McDowell F: Diphenylhydantoin metabolism, blood levels and toxicity. Arch Neurol 11:642–648, 1964.
Kutt H, Schoman GE: Phenytoin: relevant side effects. In: Glaser GH, Penry JK, Woodbury DM (eds) Antiepileptic Drugs: Mechanism of Action. Raven Press, New York, 1980.
Levantine A, Almeyda J: Cutaneous reactions to anticonvulsants. Br J Dermatol 87:646–649, 1972.
Hanson JW, Smith DW: The fetal hydantoin syndrome. J Pediatr 87:285–290, 1975.
Willius FA, Keys TE: A remarkably early reference to the use of cinchona in cardiac arrhythmia. In: Staff Meetings of the Mayo Clinic XCIV, 1942, pp 294–296.
Wenckebach KF: Die unregelmässige Herztätigkeit und ihre klinische Bedeutung. Engelmann W, Leipzig, 1914.
Frey W: Weitere Erfahrungen mit chinidin bei absoluter Herzunregelmässigkeit. Wien Klin Wochenschr 55:849–853, 1918.
Warnowicz MA, Denes P: Chronic ventricular arrhythmias: comparative drug effectiveness and toxicity. Prog Cardiovasc Dis 23:225–236, 1980.
Bloomfield SS, Romhilt DW, Chou T, Fowler NO: Natural history of cardiac arrhythmias and their prevention with quinidine in patients with acute coronary insufficiency. Circulation 47:967–973, 1973.
Bloomfield SS, Romhilt DW, Chou T, Fowler NO: Quinidine for prophylaxis of arrhythmias in acute myocardial infarction. N Engl J Med 285:979–986, 1971.
Gaughan CE, Lown B, Lanigan J, Voukydis P, Besser HW: Acute oral testing for determining antiarrhythmia drug efficacy. Am J Cardiol 38:677–684, 1976.
Jelinek MV, Lohrbauer L, Lown B: Antiarrhythmic drug therapy for sporadic ventricular ectopic arrhythmias. Circulation 49:659–666, 1974.
Winkle RA. Gradman AH, Fitzgerald JW, Bell PA: Anti- arrhythmic drug effect assessed from ventricular arrhythmia reduction in the ambulatory electrocardiogram and treadmill test: comparison of propranolol, procainamide and quinidine. Am J Cardiol 42:473–480, 1978.
Myerburg RJ, Conde C, Sheps DS, Appel RA, Kiem I, Sung RJ, Castellanos A: Antiarrhythmic drug therapy in survivors of prehospital cardiac arrest: comparison of effects on chronic ventricular arrhythmias and recurrent cardiac arrest. Circulation 59:855–863, 1979.
Kletzkin M: Antiarrhythmic therapy: quinidine gluconate vs procainamide. Circulation 61: 214, 1980.
Cramer G: Early and late results of conversion of atrial fibrillation with quinidine: a clinical and hemodynamic study. Acta Med Scand [Suppl] 490:5–96, 1968.
Sodermark T, Edhag O, Sjogren A, Jonsson B, Olsson A, Oro L, Danielsson M, Rosenhamer G, Wallin H: Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter: a multicentre study from Stockholm. Br Heart J 37:486–492, 1975.
Hillestad L, Bjerkelund C, Dale J, Maltau J, Storstein O: Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation: a controlled clinical study. Br Heart J 33:518–521, 1971.
Waris E, Kreus K, Salokannel J: Factors influencing persistence of sinus rhythm after DC shock treatment of atrial fibrillation. Acta Med Scand 189:161–166, 1971.
Wellens HJJ, Durrer D: Effect of procaine amide, quinidine, and ajmaline in the Wolff-Parkinson-White syndrome. Circulation 50:114–120, 1974.
Wellens HJJ, Bar FW, Dassen WRM, Brugada P, Vanagt EJ, Farre J: Effect of drugs in the Wolff-Parkinson-White syndrome: importance of initial length of effective refractory period of the accessory pathway. Am J Cardiol 46:665–669, 1980.
Wu D, Hung J, Kuo C, Hsu K, Shieh W: Effects of quinidine on atrioventricular nodal reentrant paroxysmal tachycardia. Circulation 64:823–831, 1981.
Hoffman BF, Rosen MR, Wit AL: Appraisal and reappraisal of cardiac therapy: electrophysiology and pharmacology of cardiac arrhythmias. VII. Cardiac effects of quinidine and procaine amide. Part A. Am Heart J 89:804–840, 1975.
Gillette PC, Garson A: Electrophysiologic and pharmacologic characteristics of automatic ectopic atrial tachycardia. Circulation 56:571–579, 1977.
Ueda CT, Hirschfeld DS, Scheinman MM, Rowland M, Williamson BJ, Dzindzio BS: Disposition kinetics of quinidine. Clin Pharmacol Ther 19:30–36, 1975.
Ochs HR, Greenblatt DJ, Woo E, Smith TW: Reduced quinidine clearance in elderly persons. Am J Cardiol 42:481–485, 1978.
Conn HL, Luchi RJ: Some quantitative aspects of the binding of quinidine and related quinoline compounds by human serum albumin. J Clin Invest 40: 509–516, 1961.
Data JL, Wilkinson GR, Nies AS: Interaction of quinidine with anticonvulsant drugs. N Engl J Med 294:699–702, 1976.
Doering W: Quinidine-digoxin interaction: pharmacokinetics, underlying mechanism and clinical implications. N Engl J Med 301:400–404, 1979.
Leahey EB, Reiffel JA, Drusin RE, Heissenbuttel RH, Lovejoy WP, Bigger JT: Interaction between quinidine and digoxin. J Am Med Assoc 240: 533–534, 1978.
Leahey EB, Reiffel JA, Heissenbuttel RH, Drusin RE, Lovejoy WP, Bigger JT: Enhanced cardiac effect of digoxin during quinidine treatment. Arch Intern Med 139: 519–521,1979.
Hirsh PD, Weiner HJ, North RL: Further insights into digoxin-quinidine interaction: lack of correlation between serum digoxin concentration and inotropic state of the heart. Am J Cardiol 46:863–867, 1980.
Bigger JT: The quinidine-digoxin interaction: what do we know about it? N Engl J Med 301: 779–781, 1979.
Ochs HR, Greenblatt DJ, Woo E, Franke K. Pfeifer HJ, Smith TW: Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate. Am J Cardiol 41: 770–777, 1978.
Hirschfeld DS, Ueda CT, Rowland M, Scheinman MM: Clinical and electrophysiological effects of intravenous quinidine in man. Br Heart J 39:309–316, 1977.
Anderson JL, Mason JW: Successful treatment of overdrive pacing of recurrent quinidine syncope due to ventricular tachycardia. Am J Med 64:715–718, 1978.
Koster RW, Wellens HJJ: Quinidine-induced ventricular flutter and fibrillation without digitalis therapy. Am J Cardiol 38:519–523, 1976.
Luchi RJ: Intoxication with quinidine. Chest 73:129–131, 1978.
Reynolds EW, Vander Ark CR: Quinidine syncope and the delayed repolarization syndromes. Mod Concepts Cardio- vasc Dis 45:117–122, 1976.
Selzer A, Wray HW: Quinidine syncope: paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30:17–26, 1964.
Grayzel J, Angeles J: Sino-atrial block in man provoked by quinidine. J Electrocardiol 5:289–294, 1972.
Mason JW, Winkle RA, Rider AK, Stinson EB, Harrison DC: The electrophysiologic effects of quinidine in the transplanted human heart. J Clin Invest 59:481 –489, 1977.
Cohen IS, Jick H, Cohen SI: Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis 20:151–163, 1977.
Nair MRS, Duvernoy WFC, Leichtman DA: Severe leukopenia and thrombocytopenia secondary to quinidine. Clin Cardiol 4: 247–257, 1981.
Yagiela JA, Benoit PW: Skeletal-muscle damage from quinidine N Engl J Med 301:437, 1979.
Moe GK, Abildskow JA: Antiarrhythmic drugs. In: Goodman LS, Gilman AG (eds) The Pharmacological Basis of Therapeutics. Macmillan, New York, 1970, pp 709–727.
Engler RL, Le Winter MM, Karliner JS: Depressant effects of quinidine gluconate on left ventricular function in conscious dogs with and without volume overload. Circulation 60:828–835, 1979.
Crawford MH, White DH, O’Rourke RA, Amon KW: Effects of oral quinidine on left ventricular performance in normal subjects and patients with congestive cardiomy- opathy. Am J Cardiol 44:714–718, 1979.
Arnsdorf M F, Bigger JT: The effect of procaine amide on components ot excitability in long mammalian cardiac Purkinje fibers. Circ Res 38:115–122, 1976.
Kastor JA, Josephson ME, Guss SB, Horowitz LN: Human ventricular refractoriness: II. Effects of procainamide. Circulation 56:462–467, 1977.
Woske H, Belford J, Fastier FN, Brooks CM: The effect of procaine amide on excitability, refractoriness and conduction in the mammalian heart. J Pharmacol Exp Ther 107:134–140, 1953.
Michelson EL, Spear JF, Moore EN: Effects of procainamide on strength-interval relations in normal and chronically infarcted canine myocardium. Am J Cardiol 47:1223 –1232,1981.
Kayden HJ, Brodie BB, Steele JM: Procaine amide: a review. Circulation 15:118–126, 1957.
Koch-Weser J, Klein SW, Foo-Canto LL, Kastor JA, De-Sanctis RW: Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction. N Engl J Med 281: 1253–1260, 1969.
Kosowsky BD, Taylor J, Lown B, Ritchie RF: Long-term use of procaine amide following acute myocardial infarction. Circulation 47:1204–1210, 1973.
Engel TR, Meister SG, Luch JC: Modification of ventricular tachycardia by procainamide in patients with coronary artery disease. Am J Cardiol 46:1033–1038, 1980.
Wellens HJJ, Bar FWHM, Lie KI, Duren DR, Dohmen HJ: Effect of procainamide, propranolol and verapamil on mechanism of tachycardia in patients with chronic recurrent ventricular tachycardia. Am J Cardiol 40:579–585, 1977.
Greenspan AM, Horowitz LN, Spielman SR, Josephson ME: Large dose procainamide therapy for ventricular tachyarrhythmia. Am J Cardiol 46:453–462. 1980.
Halpern SW, Ellrodt G, Singh BN, Mandel WJ: Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: relation to left atrial size. Br Heart J 44:589–595, 1980.
Wyse DG, McAnulty JH, Rahimtoola SH: Influence of plasma drug level and the presence of conduction disease on the electrophysiologic effects of procainamide. Am J Cardiol 43:619–626, 1979.
Wyndham CR, Meeran MK, Wu D, Rosen KM: Recent insights into paroxysmal supraventricular tachycardia - An integrated approach to disgnosis and therapy. Aust N Z J Med 7:212–231, 1977.
Koch-Weser J: Pharmacokinetics of procainamide in man. Ann NY Acad Sci 179:370–382, 1971.
Koch-Weser J, Klein SW: Procainamide dosage schedules, plasma concentrations, and clinical effects. J Am Med Assoc 215:1454–1460, 1971.
Lima JJ, Goldfarb AL, Conti DR, Golden LH, Bascomb BL, Benedetti GM, Jusko WJ: Safety and efficacy of procainamide infusions. Am J Cardiol 43:98–105, 1979.
Mattiasson I, Hanson A, Johansson BW: Massive doses of procainamide for ventricular tachyarrhythmias due to myocardial infarction. Acta Med Scand 204:27–34, 1978.
Embree LJ, Levine SA: Ventricular tachycardia: a case requiring massive amounts of procaine amide (pronestyl) for reversion. Ann Intern Med 50:222–231, 1959.
Myerburg RJ, Kessler KM. Kiem I, Pefkaros KC, Conde CA, Cooper D, Castellanos A: Relationship between plasma levels of procainamide, suppression of premature ventricular complexes and prevention of recurrent ventricular tachycardia. Circulation 64:280–290, 1981.
Fisher JD, Cohen HL, Mehra R, Altschuler H, Escher DJW, Furman S: Cardiac pacing and pacemakers. II. Serial electrophysiologic-pharmacologic testing for control of recurrent tachyarrhythmias. Am Heart J 93:658–668, 1977.
Winkle RA, Alderman EL, Fitzgerald JW, Harrison DC: Treatment of recurrent symptomatic ventricular tachycardia. Ann Intern Med 85:1–7, 1976.
Berry K, Garlett, EL, Bellet S, Gefter WI: Use of pronestyl in the treatment of ectopic rhythms-treatment of ninety- eight episodes in seventy-eight patients. Am J Med 11: 431–441,1951.
Epstein MA: Ventricular standstill during the intravenous procaine amide treatment of ventricular tachycardia. Am Heart J 45:898–908, 1953.
Stearns NS, Callahan EJ III, Ellis LB: Value and hazards of intravenous procaine amide (“pronestyl”) therapy. J Am Med Assoc 148:360–364, 1952.
Strasberg B, Sclarovsky S, Erdberg A, Duffy CE, Lam W, Swiryn S, Agmon J, Rosen KM: Procainamide-induced polymorphous ventricular tachycardia. Am J Cardiol 47:1309–1314, 1981.
Scheinman MM, Weiss AN, Shafton E, Benowitz N, Rowland M: Electrophysiologic effects of procaine amide in patients with intraventricular conduction delay. Circulation 49:522–529, 1974.
Konttinen YP, Tuominen L: Reversible procainamide-induced agranulocytosis twice in one patient. Lancet 2:925, 1971.
Blomgren SE, Condemi JJ, Vaughan JH: Procainamide- induced lupus erythematosus: clinical and laboratory observations. Am J Med 52: 338–348, 1972.
Anderson RJ, Genton E: Procainamide-induced pericardial effusion. Am Heart J 83:798–800, 1972.
Elson J, Strong JM, Lee W, Atkinson AJ: Antiarrhythmic potency of n-acetylprocainamide. Clin Pharmacol Ther 17: 134–140, 1975.
Roden DM, Reele SB, Higgins SB, Wilkinson GR, Smith RF, Oates JA, Woosley RL: Antiarrhythmic efficacy, pharmacokinetics and safety of n-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol 46:463–468, 1980.
Winkle RA, Jaillon P, Kates RE, Peters F: Clinical pharmacology and antiarrhythmic efficacy of n-acetylprocainamide. Am J Cardiol 47:123–130, 1981.
Jaillon P, Rubenson D, Peters F, Mason JW, Winkle RA: Electrophysiologic effects of n-acetylprocainamide in human beings. Am J Cardiol 47:1134–1140, 1981.
Jaillon P, Winkle RA: Electrophysiologic comparative study of procainamide and n-acetylprocainamide in anesthetized dogs: concentration-response relationships. Circulation 60:1385–1394, 1979.
Ahmad S: Procainamide, NAPA and systemic lupus (Letter to the Editor). Circulation 61:865, 1980.
Stec GP, Lertora JJL, Atkinson AJ, Nevin MJ, Kushner W, Jones C, Schmid FR, Askenazi J: Remission of procainamide-induced lupus erythematosus with n-acetylprocai- namide therapy. Ann Intern Med 90:799–801, 1979.
Winkle RA, Jaillon P: Procainamide, NAPA and systemic lupus. Circulation 61:865–866, 1980.
Mokler CM, Van Arman CG: Pharmacology of a new antiarrhythmic agent, y-diisopropyl-amino-a-phenyl-a-(2 -Pyridyl)-butyramide (SC-7031). J Pharmacol Exp Ther 136:114–124, 1962.
Kus T, Sasyniuk BI: Electrophysiological actions of diso- pyramide phosphate on canine ventricular muscle and Purkinje fibers. Circ Res 37:844–854, 1975.
Yu PN: Disopyramide phosphate (norpace): a new antiarrhythmic drug. Circulation 59:236–237, 1979.
Jennings G, Jones MBS, Besterman EMM, Model DG, Turner PP, Kidner PH: Oral disopyramide in prophylaxis of arrhythmias following myocardial infarction. Lancet 10:51–54, 1976.
Sbarbaro JA, Rawling DA, Fozzard HA: Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: efficacy comparison in a randomized trial. Am J Cardiol 44:513–520, 1979.
Vismara LA, Mason DT, Amsterdam EA: Disopyramide phosphate: clinical efficacy of a new oral antiarrhythmic drug. Clin Pharmacol Ther 16:330–335, 1974.
Benditt DG, Pritchett ELC, Wallace AG, Gallagher JJ: Recurrent ventricular tachycardia in man: evaluation of disopyramide therapy by intracardiac electrical stimulation. EurJ Cardiol 9/4:255–276, 1971.
Deano DA, Wu D, Mautner RK, Sherman RH, Ehsani AE, Rosen KM: The antiarrhythmic efficacy of intravenous therapy with disopyramide phosphate. Chest 71: 597–606, 1977.
Vismara LA, Vera Z, Miller RR, Mason DT: Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia. Am J Cardiol 39:1027–1034, 1977.
Nicholls DP, Haybyrne T, Barnes PC: Intravenous and oral disopyramide after myocardial infarction. Lancet 2:936–938, 1980.
Wilcox, RG, Hampton JR, Rowley JM, Mitchell JRA, Roland JM, Banks DC: Randomized placebo-controlled trial comparing oxprenolol with disopyramide phosphate in immediate treatment of suspected myocardial infarction. Lancet 2:765, 1980.
Zainal N, Griffiths JW, Carmichael DJS, Besterman EMM, Kidner PH, Gillham AD, Summers GD: Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards. Lancet 2:887–889, 1977.
Hartel G, Louhija A, Konttinen A: Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. Clin Pharmacol Ther 15:551–555, 1974.
Niarchos AP: Disopyramide: serum level and arrhythmia conversion. Am Heart J 92:57–64, 1976.
Bennett DH: Disopyramide in patients with the Wolff- Parkinson-White syndrome and atrial fibrillation. Chest 74:624–628, 1978.
Spurrell RAJ, Thorburn CW, Camm J, Sowton E, Deuchar DC: Effects of disopyramide on electrophysiological properties of specialized conduction system in man and on accessory atrioventricular pathway in Wolff-Parkinson- vVhite syndrome. Br Heart J 37:861–867, 1975.
Swiryn S, Bauernfeind RA, Wyndham RC, Dhingra RC, Palileo E, Strasberg B, Rosen KM: Effects of oral disopyramide phosphate on induction of paroxysmal supraventricular tachycardia. Circulation 64:169–175, 1981.
Cunningham JL, Shen DD, Shudo I, Azarnoff DL: The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet 2:373–383,1977.
Gallagher JJ, Pritchett ELC, Benditt DG, Wallace AG: High dose disopyramide phosphate: an effective treatment for refractory ventricular tachycardia. Circulation 55 (Suppl III):225, 1977.
Patterson E, Gibson JK, Lucchesi BR: Electrophysiologic effects of disopyramide phosphate on reentrant ventricular arrhythmia in conscious dogs after myocardial infarction. Am J Cardiol 46:792–799, 1980.
Simpson RJ, Foster JR, Benge C, Gettes LS: Safety of multiple bolus loading in intravenous disopyramide. Am Heart J (in press).
Dhurandhar RW, Nademanee K, Goldman AM: Ventricular tachycardia-flutter associated with disopyramide therapy: a report of three cases. Heart Lung 7:783–787, 1978.
Frieden J: Quinidine effects due to disopyramide. N Engl J Med 298: 975, 1978.
Meltzer RS, Robert EW, McMorrow M, Martin RP: Atypical ventricular tachycardia as a manifestation of disopyramide toxicity. Am J Cardiol 42:1049–1053, 1978.
Kotter V, Linderer T, Schroder R: Effects of disopyramide on systemic and coronary hemodynamics and myocardial metabolism in patients with coronary artery disease: comparison with lidocaine. Am J Cardiol 46:469–475, 1980.
Walsh RA, Horwitz LD: Adverse hemodynamic effects of intravenous disopyramide compared with quinidine in conscious dogs. Circulation 60:1053–1058, 1979.
Kinney EL, Field EH, Salmon MP, Zelis R: Cardiac arrhythmias associated with disopyramide. N Engl J Med 302:1146, 1980.
Leach AJ, Brown JE, Armstrong PW: Cardiac depression by intravenous disopyramide in patients with left ventricular dysfunction. Am J Med 68:839–844, 1980.
Hulting J, Rosenhamer G: Hemodynamic and electrocardiographic effects of disopyramide in patients with ventricular arrhythmia. Acta Med Scand 199:41–51, 1976.
Podrid PJ, Schoeneberger A, Lown B: Congestive heart failure caused by oral disopyramide. N Engl J Med 302:614–617, 1980.
Reddy CP, Benes J: Efficacy and safety of a new intravenous dosage regimen of disopyramide in treating patients with ventricular arrhythmia. Circulation 64 (Suppl): IV-265, 1981 (abstract).
Befeler B, Castellanos A,. Wells DE, Vagueiro MC, Yeh BK: Electrophysiologic effects of the antiarrhythmic agent disopyramide phosphate. Am J Cardiol 35:282–287, 1975.
Ross D, Vohra J, Cole P, Hunt D, Sloman G: Electrophysiology of disopyramide in man. Aust NZ J Med 8: 377–383, 1978.
Seipel L, Breithardt G: Sinus recovery time after disopyramide phosphate. Am J Cardiol 37:1118. 1976.
LaBarre A, Strauss HĆ, Scheinman MM, Evans GT, Bashore T, Tiedeman JS, Wallace AG: Electrophysiologic effects of disopyramide phosphate on sinus node function in patients with sinus node dysfunction. Circulation 59: 226–235, 1979.
Desai JM, Scheinman M, Peters RW, O’Young J: Electrophysiological effects of disopyramide in patients with bundle branch block. Circulation 59:215–225, 1979.
Robertson CE, Miller HC: Extreme tachycardia complicating the use of disopyramide in atrial flutter. Br Heart J 44:602–603, 1980.
Porterfield JG, Antman EM, Lown B: Respiratory difficulty after use of disopyramide. N Engl J Med 303:584, 1980.
Goldberg IJ, Brown LK, Rayfield EJ: Disopyramide (Norpace(r))-induced hypoglycemia. Am J Med 69:463–466, 1980.
Harrison DC, Winkle R, Sami M, Mason J: Encainide: a new and potent antiarrhythmic agent. Am Heart J 100: 1046–1054, 1980.
Roden DM, Reele SB, Higgins SB, Mayol RF, Gammans RE, Oates J A, Woosley RL: Total suppression of ventricular arrhythmias by encainide. N Engl J Med 302:877–882, 1980.
Kesteloot H, Stroobaudt R: Clinical experience of encainide (MJ 9067): a new anti-arrhythmic drug. Eur J Clin Pharmacol 16:323–326, 1979.
Mason JW, Peters FA: Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia. Circulation 63:670–675, 1981.
Roden DM, Duff HJ, WangT, Woosley RL: Contribution of a metabolite to the ECG and antiarrhythmic actions of encainide. Circulation 62 (Suppl III):III-141, 1980 (abstract).
Sami M, Mason JW, Peters F, Harrison DC: Electrophysiologic effects of encainide, a new antiarrhythmic drug. Am J Cardiol 44:526–532, 1979.
Metcalfe JM, Daly KM, Atkinson L, Monaghan M, Jewitt DE: Dose-related hemodynamic effects of intravenous encainide. Am J Cardiol 47:483, 1981 (abstract).
Winkle RA, Mason JW, Griffin JC, Ross D: Malignant ventricular tachyarrhythmias associated with use of encainide. Am Heart J 102: 857–864, 1981.
Bren GB, Varghese PJ, Katz RJ, Ross AM: Arrhythmoge- nicity of encainide: the role of QT interval. Am J Cardiol 47:498, 1981 (abstract).
DiBianco R, Gottdiener JS, Fletcher RD, Single S, Katz RJ, Sauerbrunn B: Effects of encainide on left ventricular function: assessmènt with treadmill exercise and radionuclide ventriculography. Circulation 62 (Suppl III):III-182, 1980.
Somani P: Antiarrhythmic effects of flecainide. Clin Pharmacol Ther 27:464–470, 1980.
Campbell RWF, Henderson A, Bryson LG, Reid DS, Sheridan DJ, Rawlins MD, Julian DG: Intravenous flecainide - Pharmacokinetics and efficacy. Circulation 64 (Suppl IV): IV-265, 1981 (abstract).
Anderson JL, Stewart JR, Perry BA, Van Hamersveld DD, Johnson TA, Conard GJ, Chang SF, Kvam DC, Pitt B: Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med 305: 473–477, 1981.
Morrison H, Haugland JM, Granrud G, Asinger RW, Mikell FL, Krejci J: Flecainide acetate, a new antiarrhythmic agent: dose-ranging and efficacy study. Am J Cardiol 47:482, 1981 (abstract).
Van Hamersveld DD, Stewart JR, Johnson TA, Anderson JL: Oral flecainide acetate for long-term treatment of ventricular arrhythmias in man. Circulation 64 (Suppl IV): IV-316, 1981 (abstract).
Granrud G, Krejci J, Coyne T, Hodges M: Sustained elimination of ventricular arrhythmias during chronic flecainide dosing. Circulation 64 (Suppl IV):IV-316, 1981 (abstract).
Conrad GJ, Carlson GL, Frost JW, Ober RE: Human plasme pharmacokinetics of flecainide acetate (R-818), a new antiarrhythmic, following single oral and intravenous doses. Clin Pharmacol Ther 25:218, 1979 (abstract).
Verdouw PD, Deckers JW, Conard GJ: Antiarrhythmic and hemodynamic actions of flecainide acetate (R-818) in the ischemic porcine heart. J Cardiovasc Pharmacol 1: 473–486,1979.
Welter AN, Schmid JR, Kvam DC: Cardiovascular profile of R-818, a new antiarrhythmic. Fed Proc 36:1003, 1977 (abstract).
Klotz U, Muller-Seydlitz PM, Heimburg P: Lorcainide infusion in the treatment of ventricular premature beats. Eur J Clin Pharmacol 16:1–6, 1979.
Sung RJ, Somani P: Discordant antiarrhythmic effects of intravenous lorcainide on ventricular premature beats and ventricular tachycardia. Circulation 64 (Suppl IV): IV-37, 1981 (abstract).
Kesteloot H, Stroobandt R: Clinical experience with lorcainide (R 15889), a new antiarrhythmic drug. Arch Intern Pharmacodyn 230:225–234, 1977.
Somberg JC, Willens H, Camilleri W, Maguire W, Miura DS: Effect of lorcainide on suppressing ventricular tachycardia induced by programmed stimulation. Circulation 64 (Suppl IV):IV-37, 1981 (abstract).
Cocco G, Strozzi C: Initial clinical experience of lorcainide (Rol3–1042), a new antiarrhythmic agent. Eur J Clin Pharmacol 14:105–109, 1978.
Meinertz T, Kasper W, Kersting F, Bechtold H, Jahnchen E, Lollgen H, Just H: Comparison of the antiarrhythmic activity of mexiletine and lorcainide on refractory ventricular arrhythmias. Circulation 62 (Suppl III):III-184, 1980 (abstract).
Morganroth J, Dreifus LS, Michelson EL, Sawin HW: Efficacy and tolerance of lorcainide. Circulation 62 (SupplIII): III-180, 1980 (abstract).
Klotz U, Muller-Seydlitz P, Heimburg P: Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent. Clin Pharmacokinet 3:407–418, 1978.
Jahnchen E, Bechtold H, Kasper W, Kersting F, Just H, Heykants J: Lorcainide: I. Saturable presystemic elimination. Clin Pharmacol Ther 26: 187–195, 1979.
Klotz U, Muller-Seydlitz P, Heimburg P: Disposition and antiarrhythmic effect of lorcainide. Int J Clin Pharmacol Biopharm 17:152–158, 1979.
Meinertz T, Kasper W, Kersting F, Just H, Bechtold H, Jahnchen E: Lorcainide: II. plasma concentration-effect relationship. Clin Pharmacol Ther 26:196–204, 1979.
Davis LD, Temte JV: Effects of propranolol on the transmembrane potentials of ventricular muscle and Purkinje fibers of the dog. Circ Res 22:661–677, 1968.
Berkowitz WD, Wit AL, Lau LH, Steiner C, Damato AN: The effects of propranolol on cardiac conduction. Circulation 40:855–862, 1969.
Gettes LS: Beta adrenergic blocking drugs in the treatment of cardiac arrhythmias. Cardiovasc Clin 2:211–237, 1970.
Lucchesi BR, Whitsitt LSm Stickney JL: Antiarrhythmic effects of beta adrenergic blocking agents. Ann NY Acad Sci 139:940–951, 1967.
Gorlin R: The hyperkinetic heart syndrome. J Am Med Assoc 182:823–829, 1962.
Schamroth L: Immediate effects of intravenous propranolol on various cardiac arrhythmias. Am J Cardiol 18:438–443, 1966.
Gibson D, Sowton E: The use of beta-adrenergic receptor blocking drugs in dysrhythmias. Prog Cardiovasc Dis 12: 16–39, 1969.
Wu D, Denes P, Dhingra R, Khan A, Rosen KM: The effects of propranolol on induction of A-V nodal reentrant paroxysmal tachycardia. Circulation 50:665–677, 1974.
Denes P, Cummings JM, Simpson R, Wu D, Amat-Y- Leon F, Dhingra R, Rosen KM: Effects of propranolol on anomalous pathway refractoriness and circus movement tachycardias in patients with preexcitation. Am J Cardiol 41:1061–1067, 1978.
Rosen KM, Barwolf C, Ehsani A, Rahimtoola SH: Effects of lidocaine and propranolol on the normal and anomalous pathways in patients with preexcitation. Am J Cardiol 30:801–809, 1972.
Walters L, Gettes LS, Noonan JA, Surawicz B: Long-term management of chronic tachycardias of childhood with orally administered propranolol. Am J Cardiol 21:119, 1968 (abstract).
Brown RW, Goble AJ: Effect of propranolol on exercise tolerance of patients with atrial fibrillation. Br Med J 2:279–280, 1969.
Luria MH, Adelson El, Miller AJ: Acute and chronic effects of an adrenergic beta-receptor blocking agent (propranolol) in treatment of cardiac arrhythmias. Circulation 34:767–773, 1966.
Sloman G, Stannard M: Beta-adrenergic blockade and cardiac arrhythmias. Br Med J 4:508–512, 1967.
Stock JPP: Beta adrenergic blocking drugs in the clinical management of cardiac arrhythmias. Am J Cardiol 18: 444–449, 1966.
Arnsdorf MF: Electrophysiologic properties of antidys- rhythmic drugs as a rational basis for therapy. Med Clin North Am 60:213–232, 1976.
Wolfson S, Herman MV, Sullivan JM, Gorlin R: Conversion of atrial fibrillation and flutter by propranolol. Br Heart J 29:305–309, 1967.
Davis LD, Temte JV, Murphy QR: Epinephrine - cyclopropane effects on Purkinje fibers. Anesthesiology 30: 369–377. 1969.
Katz RL, Epstein RA: The interaction of anesthetic agents and adrenergic drugs to produce cardiac arrhythmias. Anesthesiology 29:763–784, 1968.
Krasnow N, Barbarosh H: Clinical experiences with beta- adrenergic blocking agents. Anesthesiology 29:814–827, 1968.
Prichard BNC, Ross EJ: Use of propranolol in conjunction with alpha receptor blocking drugs in pheochromocytoma. Am J Cardiol 18:394–398, 1966.
Garza LA, Vick RL, Nora JJ, McNamara DG: Heritable Q-T prolongation without deafness. Circulation 41:39–48, 1970.
Olley PM, Fowler RS: The surdo-cardiac syndrome and therapeutic observations. Br Heart J 32:467–471, 1970.
Gettes LS, Surawicz B: Long-term prevention of paroxysmal arrhythmias with propranolol therapy. Am J Med Sci 254:257–265, 1967.
Nixon JV, Pennington W, Ritter W, Shapiro W: Efficacy of propranolol in the control of exercise-induced or augmented ventricular ectopic activity. Circulation 57:115–122,1978.
Taylor RR, Halliday EJ: Beta-adrenergic blockade in the treatment of exercise-induced paroxysmal ventricular tachycardia. Circulation 32:778–781, 1965.
Turner JRB: Propranolol in the treatment of digitalis-induced and digitalis-resistant tachycardias. Am J Cardiol 18:450–457, 1966.
Becker DJ, Nonkin PM, Bennett LD, Kimball SG, Sternberg MS, Wasserman F: Effect of isoproterenol in digitalis cardiotoxicity. Am J Cardiol 10:242–247, 1962.
Roberts J, Ito R, Reilly J, Cairoli VJ: Influence of reser- pine and /3TM 10 on digitalis-induced ventricular arrhythmia. Circ Res 13:149–158, 1963.
Greene R, Oliver LC: Sensitivity to propranolol after di- goxin intoxication. Br Med J 4:413–414, 1968.
Kupersmith J, Shiang H, Litwak RS, Herman MV: Electrophysiological and antiarrhythmic effects of propranolol in canine acute myocardial ischemia. Circ Res 38:302–307, 1976.
Stephen S A: Propranolol in acute myocardial infarction: a multicentre trial. Lancet 31:1435–1437, 1966.
Lemberg L, Castellanos A, Arcebal AG: The use of propranolol in arrhythmias complicating acute myocardial infarction. Am Heart J 80:479–487, 1970.
Shand DG: Drug therapy: propranolol. N Engl J Med 293:280–285,1975.
Naggar CZ, Alexander S: Propranolol treatment of VPB’s. N Engl J Med 294:903–904, 1976.
Winkle RA, Lopes MG, Goodman DJ, Fitzgerald JW, Schroeder JS, Harrison DC: Propranolol for patients with mitral valve prolapse. Am Heart J 93:422–427, 1977.
Woosley RL, Kornhauser D, Smith R, Reele S, Higgins SB, Nies AS, Shand DG, Oates JA: Suppression of chronic ventricular arrhythmias with propranolol. Circulation 60: 819–827, 1979.
Horowitz LN, Josephson ME, Kastor JA: Intracardiac electrophysiologic studies as a method for the optimization of drug therapy in chronic ventricular arrhythmia. Prog Cardiovasc Dis 23:81–98, 1980.
Evans GH, Shand DG: Disposition of propranolol: V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther 14:487–493, 1973.
Shand DG, Nuckolls EM, Oates JA: Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther 11:112–120, 1969.
Faulkner SL, Hopkins JT, Boerth RC, Young JL, Jellett LB, Nies AS, Bender HW, Shand DG: Time required for complete recovery from chronic propranolol therapy. N Engl J Med 289:607–609, 1973.
Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Cirksena WJ: Pharmacokinetics of propranolol in chronic renal disease. Clin Pharmacol Ther 16:761–769, 1974.
Thompson FD, Joekes AM, Foulkes DM: Pharmacodynamics of propranolol in renal failure. Br Med J 2:434–436, 1972.
Fitzgerald JD, O’Donnell S, Austin M: Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol. Br J Pharmacol 43:222–235, 1971.
Walle T, Gaffney TE: Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. J Pharmacol Exp Ther 182:83–92, 1972.
Coltart DJ, Shand DG: Plasma propranolol levels in the quantitative assessment of )3-adrenergic blockade in man. Br Med J 3:731–734, 1970.
David D, Di Segni E, Klein HO, Kaplinsky E: Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation. Chest 71:592–596, 1977. nergic blocking agent. Am J Cardiol 44:1378–1382, 1979.
Yahalom J, Klein H, Kaplinsky E: Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation. Chest 71:592–596, 1977.
Gettes LS, YoshonisKF: Rapidly recurring supraventricular tachycardia: a manifestation of reciprocating tachycardia and an indication for propranolol therapy. Circulation 41:689–700, 1970.
Stern S: Conversion of chronic atrial fibrillation to sinus rhythm with combined propranolol and quinidine treatment. Am Heart J 74:170–172, 1967.
Stern S: Treatment and prevention of cardiac arrhythmias with propranolol and quinidine. Br Heart J 33:522–525, 1971.
Visioli O, Bertaccini G: Combined propranolol and quinidine treatment in cardiac arrhythmias. Am Heart J 75:719, 1968.
Hillestad L, Storstein O: Conversion of chronic atrial fibrillation to sinus rhythm with combined propranolol and quinidine treatment. Am Heart J 77:137–139, 1969.
Korte DW, Nash CB: Ventricular electrophysiology of quinidine-propranolol combinations in the dog heart. J Pharmacol Exp Ther 197:452–457, 1976.
Ikram H, Nixon PGF: Propranolol in myocardial infarction. Lancet 19:1134, 1966.
Williams EMV, Bagwell EE, Singh BN: Cardiospecificity of /3-receptor blockade: a comparison of the relative potencies on cardiac and peripheral vascular /?-adrenoceptors of propranolol, of practolol and its ortho-substituted isomer, and of oxprenolol and its para-substituted isomer. Cardiovasc Res 7:226–240, 1973.
McNeill RS, Ingram CG: Effect of propranolol on ventilatory function. Am J Cardiol 18:473–475, 1966.
Chidsey CA, Braunwald E, Morrow AG: Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Am J Med 39:442–451, 1965.
Vogel JHK, Chidsey CA: Cardiac adrenergic activity in experimental heart failure assessed with beta receptor blockade. Am J Cardiol 24:198–208, 1969.
Parmley WW, Braunwald E: Comparative myocardial depressant and anti-arrhythmic properties of d-propranolol, dl-propranolol and quinidine. J Pharmacol Exp Ther 158: 11–21,1967.
Port S, Cobb FR, Jones RH: Effects of propranolol on left ventricular function in normal men. Circulation 61:358–366, 1980.
Crawford MH, Lindenfeld J, O’Rourke RA: Effects of oral propranolol on left ventricular size and performance during exercise and acute pressure loading. Circulation 61: 549–554, 1980.
Parker JO, West RO, Di Giorgi S: Hemodynamic effects of propranolol in coronary heart disease. Am J Cardiol 21:11–19, 1968.
Wolfson S, Gorlin R: Cardiovascular pharmacology of propranolol in man. Circulation 40:501–511, 1969.
Conolly ME, Kersting F, Dollery CT: The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis 19:203–234, 1976.
Buiumsohn A, Eisenberg ES, Jacob H, Rosen N, Bock J, Frishman WH: Seizures and intraventricular conduction defect in propranolol poisoning: a report of two cases. Ann Intern Med 91:860–862, 1979.
Kotler MN, Berman L, Rubenstein AH: Hypoglycaemia precipitated by pronanolol. Lancet 24:1389–1390, 1966.
Kurland ML: Organic brain syndrome with propranolol. NEngl J Med 300:366, 1979.
Frohlich ED, Tarazi RC, Dustan HP: Peripheral arterial insufficiency: a complication of beta-adrenergic blocking therapy. J Am Med Assoc 208:2471–2472, 1969.
Sandler G, Clayton GA, Thornicroft SG: Clinical evaluation of verapamil in angina pectoris. Br Med J 3:224–227, 1968.
Antman EM, Stone PH, Muller JE, Braunwald E: Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: basic and clinical electrophysiologic effects. Ann Intern Med 93:875–885, 1980.
Chen CM, Gettes LS: Effects of verapamil on rapid Na channel-dependent action potentials of K+-depolarized ventricular fibers. J Pharmacol Exp Ther 290:415–421, 1979.
Gettes LS, Saito T: Effect of antiarrhythmic drugs on the slow inward current system. In: Zipes DP, Bailey JC, Elharrar V (eds) The Slow Inward Current and Cardiac Arrhythmias. Martinus Nijhoff, The Hague, 1980, pp 455–477.
Nayler WG, Szeto J, Berry D: Effect of verapamil on contractility, oxygen utilization, and calcium exchangeability in mammalian heart muscle. Cardiovasc Res 6: 120–128, 1972.
Rosen MR, Wit AL, Hoffman BF: Electrophysiology and pharmacology of cardiac arrhythmias. VI. Cardiac effects of verapamil. Am Heart J 89:665–673, 1975.
Saito S, Chen CM, Buchanan J, Gettes LS, Lynch MR: Steady state and time-dependent slowing of conduction in canine hearts - Effects of potassium and lidocaine. Circ Res 42:246–254, 1978.
Henry PD: Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am J Cardiol 46:1047–1058, 1980.
Husaini MH, Kvasnicka J, Ryden L, Holmberg S: Action of verapamil on sinus node, atrioventricular, and intraven- tricular conduction. Br Heart J 35:734–737, 1973.
Haeusler G: Differential effect of verapamil on excitation- -contraction coupling in smooth muscle and on excitation -secretion coupling in adrenergic nerve terminals. J Pharmacol Exp Ther 180:672–682, 1972.
Smith HJ, Goldstein RA, Griffith JM, Kent KM, Epstein SE: Regional contractility: selective depression of ischemic myocardium by verapamil. Circulation 45:629–635, 1976.
Ferlinz J, Easthope JL, Aronow WS: Effects of verapamil on myocardial performance in coronary disease. Circulation 59:313–319, 1979.
Chew CYC, Hecht HS, Collett JT, McAllister RG, Singh BN: Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol 47: 917–922, 1981.
Singh SN, Roche AHG: Effects of intravenous verapamil on hemodynamics in patients with heart disease. Am Heart J 94:593–599, 1977.
Schamroth L, Krikler DM, Garrett C: Immediate effects of intravenous verapamil in cardiac arrhythmias. Br Med J 1:660–662, 1972.
Klein HO, Pauzner H, Segni ED, David D, Kaplinsky E: The beneficial effects of verapamil in chronic atrial fibrillation. Arch Intern Med 139:747–749, 1979.
Dominic J, McAllister RG Jr, Kuo CS, Reddy CP, Surawicz B: Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter. Clin Pharmacol Ther 26:710–714, 1979.
Heng MK, Singh BN, Roche AHG, Norris RM, Mercer CJ: Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. Am Heart J 90: 487–498,1975.
Stone PH, Antman EM, Muller JE, Braunwald E: Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II. Hemodynamic effects and clinical applications. Ann Intern Med 93:886–904, 1980.
Lazzara R, Scherlag B: Treatment of arrhythmias by blocking slow current. Ann Intern Med 93:919–921, 1980.
Sung RJ, Elser B, McAllister RG Jr: Intravenous verapa- milfor termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med 93:682–689, 1980.
Singh BN, Ellrodt G, Peter CT: Verapamil: a review of its pharmacological properties and therapeutic use. Drugs 15:169–197, 1978.
Spurrell RAJ, Krikler DM, Sowton E: Concealed bypasses of the atrioventricular node in patients with paroxysmal supraventricular tachycardia revealed by intracardiac electrical stimulation and verapamil. Am J Cardiol 33:590–595, 1974.
Wellens HJJ, Tan SL, Bar FWH, Curen DR, Lie KI, Dohmen HM: Effect of verapamil studied by programmed electrical stimulation of the heart in patients with paroxysmal re-entrant supraventricular tachycardia. Br Heart J 39:1058–1066,1977.
Porter, CJ, Gillette PC, Garson A, Hesslein PS, Karpawich PP, McNamara DG: Effects of verapamil on supraventricular tachycardia in children. Am J Cardiol 48: 487–491, 1981.
Soler-Soler J, Sagrista-Sauleda J, Cabrera A, Sauleda-Pares J, Iglesias-Berengue J, Permanyer-Miralda G, Roca-Llop J: Effect of verapamil in infants with paroxysmal supraventricular tachycardia. Circulation 59: 876–879,1979.
Matsuyama E, Konishi T, Okazaki H, Matsuda H, Kawai C: Effects of verapamil on accessory pathway properties and induction of circus movement tachycardia in patients with the Wolff-Parkinson-White syndrome. J Cardiovasc Pharmacol 3:11–24, 1981.
Spurrell RAJ, Krikler DM, Sowton E: Effects of verapamil on electrophysiological properties of anomalous atrioventricular connexion in Wolff-Parkinson-White syndrome. Br Heart J 36:256–264, 1974.
Sellers TD, Bashore TM, Gallagher JJ: Digitalis in the pre-excitation syndrome: analysis during atrial fibrillation. Circulation 56:260–267, 1977.
Opie LH: Drugs and the heart. III. Calcium antagonists. Lancet 1:806–809, 1980.
Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M: Physiological disposition of verapamil in man. Cardiovasc Res 10:605–612, 1976.
Eichelbaum M, Ende M, Remberg G, Schomerus M, Dengler HJ: The metabolism of DL-[,4C]verapamil in man. Drug Metab Dispos 7:145–148, 1979.
McAllister RG, Howell SM: Fluorometric assay of verapamil in biological fluids and tissues. J Pharm Sci 65:431 – 432,1976.
Mangiardi LM, Hariman RJ, McAllister RG Jr, Bhargava V, Surawicz B, Shabetai R: Electrophysiologic and hemodynamic effects of verapamil. Circulation 57:366–372,1978.
Woodcock BG, Hopf R, Kaltenbach M: Verapamil and norverapamil plasma concentrations during long-term therapy in patients with hypertrophic obstructive cardiomyopathy. J Cardiovasc Pharmacol 2:17–23, 1980.
Eichelbaum M, Birkel P, Grube E, Gutgemann U, Somogyi A: Effects of verapamil on P-R intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment. Klin Wo- chenschr 58:919–925, 1980.
Koike Y, Shimamura K, Shudo I, Saito H: Pharmacokinetics of verapamil in man. Res Commun Chem Pathol Pharmacol 24:37–47, 1979.
Klein HO, Lang R, Segni ED, Kaplinsky E: Verapamil-di- goxin interaction. N Engl J Med 303:160, 1980.
Leon MB, Rosing DR, Bonow RO, Lipson LC, Epstein SE: Clinical efficacy of verapamil alone and combined with propranolol in treating patients with chronic stable angina pectoris. Am J Cardiol 48:131–139, 1981.
Urthaler F, James TN: Experimental studies on the pathogenesis of asystole after verapamil in the dog. Am J Cardiol 44:651–656, 1979.
Abinader EG, Berger A: Verapamil and PSVT. Circulation 60:1198–1199, 1979.
Benaim ME: Asystole after verapamil. Br Med J 2: 169–170, 1972.
Hagemeijer F: Verapamil in the management of supraventricular tachyarrhythmias occurring after a recent myocardial infarction. Circulation 57:751–755, 1978.
Grendahl H, Miller M, Sivertssen E: Registration of sinus node recovery time in patients with sinus rhythm and in patients with dysrhythmias. Acta Med Scand 197:403–408, 1975.
Hariman RJ, Mangiardi LM, McAllister RG Jr, Surawicz B, Shabetai R, Kishida H: Reversal of the cardiovascular effects of verapamil by calcium and sodium: differences between electrophysiologic and hemodynamic responses. Circulation 59:797–804, 1979.
Gluskin LE, Strasberg B, Shah JH: Verapamil-induced hyperprolactinemia and galactorrhea. Ann Intern Med 95:66–67, 1981.
Danilo P: Aprindine. Am Heart J 97:119–124, 1979.
Zipes DP, Elharrar V, Gilmour RF, Heger JJ, Prystowsky EN: Studies with aprindine. Am Heart J 100:1055–1062, 1980.
Kesteloot H, Van Mieghem W, De Geest H: Aprindine (AC 1802), a new anti-arrhythmic drug. Acta Cardiol 28:145–165, 1974.
Fasola AF, Carmichael R: The pharmacology and clinical evaluation of aprindine, a new antiarrhythmic agent. Acta Cardiol Suppl 18:317–333, 1974.
Van Durme JP, Rousseau M, Mbuyamba P: Treatment of chronic ventricular dysrhythmias with a new drug: aprindine (AC 1802). Acta Cardiol Suppl 18:335–340, 1974.
Breithardt G, Gleichmann U, Seipel L, Loogen F: Longterm oral antiarrhythmic therapy with aprindine (AC 1802). Acta Cardiol Suppl 18:341–353, 1974.
Besse P, Giraudel JL, Grosgogeat Y, Haiat R, Puech P, Saulnier JP: Traitement des troubles du rhythme par l’a- prindine. Acta Cardiol Suppl 18:389–407, 1974.
Hagemeijer F, Janse C, Hugenholtz PG: Efficacité antia- rythmique de l’aprindine à la phase aiguë de l’infarctus du myocarde. Acta Cardiol Suppl 18:409–421, 1974.
Fasola AF, Noble RJ, Zipes DP: Treatment of recurrent ventricular tachycardia and fibrillation with aprindine. Am J Cardiol 39:903–909, 1977.
Strasberg B, Palileo E, Prechel D, Bauernfeind R, Swiryn S, Wyndham CR, Dhingra R, Kehoe R, Rosen KM: Ventricular tachycardia: prediction of response to oral aprindine with intravenous aprindine. Am J Cardiol 47: 676–682, 1981.
Wei JY, Bulkley BH, Schaeffer AH, Greene HL, Reid PR: Mitral valve prolapse syndrome and recurrent ventricular tachyarrhythmias. Ann Intern Med 89:6–9, 1978.
Troup PJ, Zipes DP: Aprindine treatment of recurrent ventricular tachycardia in patients with mitral valve prolapse. Am Heart J 97:322–328, 1981.
Bollen G, Enderle J: Preliminary experience in the treatment of cardiac arrhythmias with aprindine. Acta Cardiol Suppl 18:355–360, 1974.
Palma-Gamiz JL, Boedo C, Lopez-Pujol FJ, de Uria JS: Etude clinique d’un nouvel anti-arhythmique: aprindine. Acta Cardiol Suppl 18:361–368, 1974.
Zipes DP, Gaum WE, Foster PR, Rosen KM, Wu D, Amat-Y-Leon F, Noble RJ: Aprindine for treatment of supraventricular tachycardia with particular application to Wolff-Parkinson-White syndrome. Am J Cardiol 40:586–596, 1977.
Murphy PJ: Metabolic pathways of aprindine. Acta Cardiol Suppl 18:131–142, 1974.
Fasola AF, Carmichael R: The pharmacology and clinical evaluation of aprindine, a new antiarrhythmic agent. Acta Cardiol Suppl 18: 317–335, 1974.
Delcroix C, Martin L, Van Durme JP, Kesteloot H, Hagemeijer F, Mbuyamba P, Deblecker M: Model for exchange kinetics of aprindine in man after single and multiple doses. Acta Cardiol Suppl 18:177–194, 1974.
Rosenberg P, Fisher J, Furman S, Scheuer J: Unexpected disopyramide toxicity. Circulation 60 (Suppl II):II- 183, 1979 (abstract).
Brandes J-W, Schmitz-Moormann PS, Lehmann F-G, Martini GA: Gelbsucht nach aprindin: eine hepatitisähn- liche Arzneimittelschädigung. Dtsch Med Wochenschr 101:111–113, 1976.
Elewaut A, Van Durme JP, Goethals L, Kauffman JM, Mussche M, Elinck W, Roels H, Bogaert M, Barbier F: Aprindine-induced liver injury. Acta Gastroenterol Belg 40:236–243, 1977.
Herlong HF, Reid PR, Boitnott JK, Maddrey WC: Aprindine hepatitis. Ann Intern Med 89:359–361, 1978.
van Leeuwen R, Meyboom RHB: Agranulocytosis and aprindine (letter). Lancet 2:1137, 1976.
van Leeuwen R: Agranulocytose tijdens het gebruik van aprindine. Ned Tijdschr Geneeskd 120:1549–1550, 1976.
Baedeker W, Rastetter J: Agranulozytose nach Aprindin- behandlung. Miinch Med Wochenschr 119:1047–1048, 1977.
Brutsaert PL: Effects of aprindine on myocardial contractility. Acta Cardiol Suppl 18:91–99, 1974.
Gerin M, Gerin Y, Duvernay G, Georges A: Effects of aprindine (AC 1802) on cardiac function in conscious dogs. Acta Cardiol Suppl 18:143–162, 1974.
Mertens HM, Neuhaus KL: Investigation on the cardiovascular effects of aprindine. Acta Cardiol Suppl 18: 163–169, 1974.
Remme WJ, Verdouw PD: Cardiovascular effects of aprindine, a new antiarrhythmic drug. Eur J Cardiol 3:307–313, 1975.
Piessens J, Willems J, Kesteloot H, de Geest H: Effects of aprindine on left ventricular contractility in man. Acta Cardiol Suppl 18:203–216, 1974.
Vastesaeger M, Gillot P, Rasson G: Etude clinique d’une nouvelle médication anti-angoreuse. Acta Cardiol 22: 483–500, 1967.
Marcus FI, Fontaine GH, Frank R, Grosgogeat Y: Clinical pharmacology and therapeutic applications of the antiarrhythmic agent, amiodarone. Am Heart J 101:480–493, 1981.
Dreifus LS, Ogawa S: Quality of the ideal antiarrhythmic drug. Am J Cardiol 39:466–468, 1977.
Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, Lazzari JR, Elizari MV: Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 38:934–944, 1976.
Rowland E, Krikler DM: Electrophysiological assessment of amiodarone in treatment of resistant supraventricular arrhythmias. Br Heart J 44:82–90, 1980.
Ward DE, Camm AJ, Spurrell RAJ: Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. Br Heart J 44:91–95, 1980.
Wheeler PJ, Puritz R, Ingram DV, Chamberlain DA: Amiodarone in the treatment of refractory supraventricular and ventricular arrhythmias. Postgrad Med J 55:1–9, 1979.
Podrid PJ, Lown B: Amiodarone therapy in symptomatic sustained refractory atrial and ventricular tachyarrhythmias. Am Heart J 101:374–379, 1981.
Leak D, Eydt JN: Control of refractory arrhythmias with amiodarone. Arch Intern Med 139:425–428, 1979.
Troup PJ, Zipes DP: Amiodarone in patients with drug resistant ventricular tachyarrhythmias. Clin Res 26:655A, 1978 (abstract).
Groh, WC, Kastor JA, Josephson ME, Horowitz LN: Amiodarone: an effective drug for refractory ventricular tachycardia. Circulation 62 (Suppl III):III-152, 1980 (abstract).
Heger JJ, Prystowsky EN, Rinkenberger RL, Jackman WM, Naccarelli G, Zipes DP: Amiodarone - clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 305:539–545, 1981.
Nademanee K, Hendrickson JA, Cannom DS, Goldreyer BN, Singh BN: Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. Am Heart J 101:759–768, 1981.
Edwards AC, Shenasa M, Curry PVL, Sowton E: Amiodarone in management of chronic refractory ventricular tachycardia. Br Heart J 42:236, 1979 (abstract).
Nademanee K, Cannom D, Hendrickson J, Goldreyer B, Singh B: Recurrent sudden arrhythmic cardiac deaths prevented by amiodarone: efficacy predictable by the initial suppression of ventricular tachyarrhythmias. Circulation 64 (Suppl IV):IV-36, 1981 (abstract).
Peter T, Hamer A, Weiss D, Mandel W: Sudden death survivors: experience with long-term empiric therapy with amiderone. Circulation 64 (Suppl IV):IV-36, 1981 (abstract).
Morady F, Scheinman M, Hess D: Amiodarone in the management of patients with malignant ventricular arrhythmias. Circulation 64 (Suppl IV):IV-36, 1981 (abstract).
Kaski JC, Girotti LA, Messutti H, Rutitzky B, Rosenbaum MB: Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone. Circulation 64:273–279, 1981.
Rowland E, McKenna W, Holt D, Harris L, Krikler D: Control of the ventricular response with oral amiodarone in patients with rapidly conducted atrial fibrillation complicating the Wolff-Parkinson-White syndrome. Circulation 64 (Suppl IV):IV-317, 1981 (abstract).
Benaim R, Denizeau J-P, Melon J, Domengie B, Kolsky H, Chapelle M, Chiche P: Les effets antiarhythmiques de l’amiodarone injectable: à propos de 100 cas. Arch Mai Coeur 69:513–522, 1976.
Benaim R, UzanC: Les effets antiarrhythmiquesdel’amiod arone injectable: à propos de 153 cas. Rev Med 19:1959, 1978.
Waleffe A, Bruninx P, Kulbertus HE: Effects of amiodarone studied by programmed electrical stimulation of the heart in patients with paroxysmal re-entrant supraventricular tachycardia. J Electrocardiol 11:253–260, 1978.
Rotmensch HH, Belhassen B, Ferguson RK: Amiodarone- benefits and risks in perspective. Am Heart J 104:11171119, 1982.
Gomes J, Kang P, Behl A, Lyons J, El-Sherif N: Intravenous amiodarone: a potent and effective drug for atrioventricular nodal reentrant paroxysmal tachycardia. Circulation 64 (Suppl IV):IV-317, 1981 (abstract).
Pritchard DA, Singh BN, Hurley PJ: Effects of amiodarone on thyroid function in patients with ischaemic heart disease. Br Heart J 37:856–860, 1975.
Haffajee C, Lesko L, Canada A, Alpert JS: Clinical pharmacokinetics of amiodarone. Circulation 64 (Suppl IV): IV-263, 1981 (abstract).
Kannan R, Nademanee K, Hendrickson JA, Rostami HJ, Singh BN: Amiodarone kinetics after oral doses. Clin Pharmacol Ther 31:438–444, 1982.
Harris L, McKenna WJ, Rowland E, Storey GCA, Kvikier DM, Holt DW: Plasma amiodarone and desethyl amiodarone levels in chronic oral therapy. Circulation 64 (SupplIV): IV-263, 1981 (abstract).
Harris L, McKenna WJ, Rowland E, Holt DW, Storey GCA, Krikler DM: Side effects of long-term amiodarone therapy. Circulation 67:45–51, 1983.
Saal AK, Werner JA, Gross BW, Gorham JR, Graham EL, Sears GK, Greene HL: Interaction of amiodarone with quinidine and procainamide. Circulation (Suppl II):II- 224, 1982 (abstract).
Rakita L, Sobol SM: Amiodarone treatment for refractory arrhythmias: dose-ranging and importance of high initial dosage. Circulation 64 (Suppl IV):IV-263, 1981.
Cote P, Bourassa MG, Delaye J, Janin A, Froment R, David P: Effects of amiodarone on cardiac and coronary hemodynamimics and on myocardial metabolism in patients with coronary artery disease. Circulation 59:1165 –1172, 1979.
Sicart M, Besse P, Choussat A, Bricaud H: Action hémo- dynamique de l’amiodarone intra-veineuse chez l’homme. Arch Mai Coeur 70:219–227, 1977.
Nademanee K, Melmed S, Hendrickson J, Reed AW, Hershman JM, Singh BN: Role of serum T4 and reversed T3 in monitoring antiarrhythmic efficacy and toxicity of amiodarone in resistant arrhythmias. Am J Cardiol 47:482, 1981 (abstract).
Marchlinski FE, GanslerTS, Waxman HL, Josephson ME: Amiodarone pulmonary toxicity. Ann Intern Med 97: 839–845, 1982.
Bacaner MB: Bretylium tosylate for suppression of induced ventricular fibrillation. Am J Cardiol 17:528–534, 1966.
Bacaner MB: Treatment of ventricular fibrillation and other acute arrhythmias with bretylium tosylate. Am J Cardiol 21:530–543, 1968.
Boura ALA, Green AF: The actions of bretylium: adrenergic neurone blocking and other effects. Br J Pharmacol 14:536–548, 1959.
Wit AL, Steiner C, Damato AN: Electrophysiologic effects of bretylium on single fibers of the canine specialized conducting system and ventricle. J Pharmacol Exp Ther 173:344–356, 1970.
Bigger JT Jr, Jaffe CC: The effect of bretylium tosylate on the electrophysiologic properties of ventricular muscle and Purkinje fibers. Am J Cardiol 27:82–92, 1971.
Cardinal R, Sasynink BI: Electrophysiologic effects of bretylium tosylate on subendocardial Purkinje fibers from infarcted canine hearts. J Pharmacol Exp Ther 204: 159–174,1978.
Patterson E, Gibson JK, Lucchesi BR: Prevention of chronic canine ventricular tachyarrhythmias with bretylium tosylate. Circulation 64:1045–1050, 1981.
Allen JD, Zaidi S A, Shanks RG, Pentridge JF: The effects of bretylium on experimental cardiac dysrhythmias. Am J Cardiol 29:641–649, 1972.
Aravindakshan V, Gettes LS: effects of bretylium and lidocaine on ventricular fibrillation in the isolated rabbit heart. Cardiovasc Res 9:19–28, 1975.
Chatterjee K, Mandèl WJ, Vyden JK, Parmley WW, Forrester JS: Cardiovascular effects of bretylium tosylate in acute myocardial infarction. J Am Med Assoc 223:757–760, 1973.
Taylor SH, Donald KW: The circulatory effects of bretylium in man. Br Heart J 22:588–590, 1960.
Bernstein JG, Koch-Weser J: Effectiveness of bretylium tosylate against refractory ventricular arrhythmias. Circulation 45:1024–1034, 1972.
Cohen HC, Gozo EG, Langendorf R, Kaplan BM, Chan A, Pick A, (jlick G: Response of resistant ventricular tachycardia to bretylium: relation to site of ectopic focus and location of myocardial disease. Circulation 47:331–340, 1973.
Djiramdjar RW, Teasdale SJ, Mahon WA: Bretylium tosylate in the management of refractory ventricular fibrillation. Can Med Assoc J 105:161–166, 1971.
Day HW, Bacaner M: Use of bretylium tosylate in the management of acute myocardial infarction. Am J Cardiol 27:177–189, 1971.
Sanna G, Arcidiacono R: Chemical ventricular defibrillation of the human heart with bretylium tosylate. Am J Cardiol 32:982–987, 1973.
Haynes RE, Chinn TL, Copass MK, Cobb LA: Comparison of bretylium tosylate and lidocaine in management of out of hospital ventricular fibrillation: a randomized clinical trial. Am J Cardiol 48:353–360, 1981.
Koch-Weser J: Drug therapy: bretylium. N Engl J Med 300:473–477, 1979.
Romhilt DW, Bloomfield SS, Lipicky RJ, Welch RM, Fowler O: Evaluation of bretylium tosylate for the treatment of premature ventricular contractions. Circulation 45:800–807, 1972.
Anderson JT, Patterson, Wagner JG, Stewart JR, Belm HL, Lucchesi BR: Oral and intravenous bretylium disposi tion. Clin Pharmacol Ther 28:468–476, 1980.
Bacaner MB: Quantitative comparison of bretylium with other antifibrillatory drugs. Am J Cardiol 21:504–512, 1968.
The Coronary Drug Project Research Group: Prognostic importance of premature beats following myocardial infarction: experience in the Coronary Drug Project. J Am Med Assoc 223:1116–1124, 1973.
Kotler MN, Tabatznik B, Mower MM, Tominaga S: Prognostic significance of ventricular ectopic beats with respect to sudden death in the late postinfarction period. Circulation 47:959–966, 1973.
Hinkle LE, Carver ST, Argyros DC: The prognostic significance of ventricular premature contractions in healthy people and in people with coronary heart disease. Acta Cardiol (Suppl 18):5–53, 1974.
Ruberman W, Weinblatt E, Goldberg JD, Frank CW, Shapiro S: Ventricular premature beats and mortality after myocardial infarction. N Engl J Med 297:750–757, 1977.
Moss AJ: Clinical significance of ventricular arrhythmias in patients with and without coronary artery disease. Prog Cardiovasc Dis 23:33–52, 1980.
Lown B: Sudden cardiac death: the major challenge confronting contemporary cardiology. Am J Cardiol 43: 313–328, 1979.
Cobb LA, Werner JA, Trobaugh GB: Sudden cardiac death. I. A decade’s experience with out-of-hospital resuscitation. Mod Concepts Cardiovasc Dis 49:31–36, 1980.
Cobb LA, Werner JA, Trobaugh GB: Sudden cardiac death. II. Outcome of resuscitation management, and future directions. Mod Concepts Cardiovasc Dis 49:37–42, 1980.
Josephson ME, Horowitz LN, Farshidi A: Continuous local electrical activity: a mechanism of recurrent ventricular tachycardia. Circulation 57:659–665, 1978.
Simson MB: Use of signals in the terminal QRS complex to identify patients with ventricular tachycardia after myocardial infarction. Circulation 64:235–242, 1981.
Greene HL, Reid PR, Schaeffer AH: The repetitive ventricular response in man: a predictor of sudden death. N Engl J Med 299:729–734, 1978.
Schaeffer AH, Greene HL, Reid PR: Suppression of the repetitive ventricular response: an index of long-term antiarrhythmic effectiveness of aprindine for ventricular tachycardia in man. Am J Cardiol 42:1007–1012, 1978.
Reynolds JL, Whitlock RML: Effects of a beta-adrenergic receptor blocker in myocardial infarction treated for one year from onset. Br Heart J 34:252–259, 1972.
Wilhelmsson C, Vedin JA, Wilhelmsen L, Tibblin G, Werko L: Reduction of sudden deaths after myocardial infarction by treatment with alprenolol: preliminary results. Lancet 2:1157–1160, 1974.
Andersen MP, Bechsgaard P, Frederiksen J: Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction: preliminary results. Lancet 2:865–868, 1979.
Multicentre International Study: Improvement in prognosis of myocardial infarction bv long-term beta-adrenore- ceptor blockade using practolol: a multicentre international study. Br Med J 3:735–740, 1975.
Multicentre International Study: Reduction in mortality with long-term beta-adrenoceptor blockade: a multicentre international study. Br Med J 2:49–51, 1977.
The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304:801–807, 1981.
Hjalmarson A, Herlitz J, Malek I, Ryden L, Vedin A, Waldenstrom A, Wedel H, Elmfeldt D, Holmberg S, Nyberg G, Swedberg K, Waagstein F, Waldenstrom J, Wilhelmsen L, Wilhelmsson C: Effect on mortality of metoprolol in acute myocardial infarction: a double-blind randomised trial. Lancet 2:823–826, 1981.
Baber NS, Wainwright ED, Howitt G: Multicentre postinfarction trial of propranolol in 49 hospitals in the United Kingdom, Italy and Yugoslavia. Br Heart J 44:96–100, 1980.
Wilcox RG, Roland JM, Banks DC, Hampton JR, Mitchall JRA: Randomised trial comparing propranolol with atenolol in immediate treatment of suspected myocardial infarction. Br Med J 2:885–888, 1980.
β-Blocker Heart Attack Trial Research Group: A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. J Am Med Assoc 247:1707–1714, 1982.
Snow PJD, Mane MD: Effect of propranolol in myocardial infarction. Lancet 11:551–553, 1965.
Balcon R, Jewitt DE, Davies JPH, Oram S: A controlled trial of propranolol in acute myocardial infarction. Lancet 11:917–920, 1966.
A Multicentre Trial: Propranolol in acute myocardial infarction. Lancet 11:1435–1438, 1966.
Norris RM, Caughey DE, Scott PJ: Trial of propranolol in acute myocardial infarction. Br Med J 2:398–400, 1968.
The Anturane Reinfarction Trial Research Group: Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 302:250–256, 1980.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Martinus Nijhoff Publishers, Boston, The Hague, Dordrecht, Lancaster
About this chapter
Cite this chapter
Gettes, L.S., Foster, J.R., Simpson, R.J. (1983). Clinical use of antiarrhythmic drugs. In: Rosen, M.R., Hoffman, B.F. (eds) Cardiac therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3855-0_8
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3855-0_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3857-4
Online ISBN: 978-1-4613-3855-0
eBook Packages: Springer Book Archive